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[57] ABSTRACT 
Peptidyl derivatives of diesters of a-aminoalkylphosphonic 
acids with basic substitutents, their use in inhibiting serine 
proteases with trypsin-like specificity and their roles as 
anti-inflammatory agents, anticoagulants, and anti-tumor 
agents. 
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BASIC a-AMINOALKYLPHOSPHONATE 
DERIVATIVFS 
STAI'EMENT OF GOVERNMENT INTEREST 
This invention was made with government support under 
5 
2 
acid is Trp, Tyr, Phe, Met, Leu or other amino acid residue 
which contain an aromatic or large alkyl side chain. All of 
the above enzymes have extensive secondary specificity and 
recognize amino acid residues removed from the Pl residue. 
It is a further object of this invention to define new 
protease inhibitors, especially inhibitors for chymotrypsin 
and chymotrypsin-like enzymes, elastase inhibitors, blood 
coagulation enzyme inhibitors and tryptase inhibitors. These 
inhibitors are useful for controlling tumor invasion, blood 
Grants No. IIl.34035 and .HL29307 awarded by the National 
Heart, Lung and Blood Institute of the National Institutes of 
Health and by the U.S. Anny Medical Research and Devel-
opment Command, Department of the Anny, under Research 
Contract No. DADD17-89-C-9008. The government has 
certain rights in the invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
10 coagulation and various inflammatory conditions mediated 
by serine proteases. The inhibitors of this invention would 
be useful for treating diseases such as vascular clotting, 
intimations, tumor invasion, pancreatitis, emphysema or 
infantile and adult respiratory distress syndrome. The inhibi-
This invention relates to a novel class of peptidyl deriva-
tives of aromatic diesters of a-aminoalkylphosphonic acids 
useful for selectively inhibiting elastase, selectively inhib-
iting chymotrypsin-like enzymes and selectively inhibiting 
15 tors of this invention would also be useful for controlling 
hormone processing by serine proteases and for treating 
diseases related to tryptases such as inflammation and skin 
blistering. 
trypsin-like enzymes. The diesters of 20 
It is yet another object of this invention to define a novel 
group of specific inhibitors useful in vitro for inhibiting 
trypsin, elastase, chymotrypsin and other serine proteases of 
similar specificity. Such inhibitors could be used to identify 
new proteolytic enzymes encountered in research. They 
could also be used in research and industrially to prevent 
undesired proteolysis that occurs during the production, 
isolation, purification, transport and storage of valuable 
peptides and proteins. Such proteolysis often destroys or 
alters the activity and/or function of the. peptides and pro-
teins. Uses would include the addition of the inhibitors to 
a-aminoalkylphosphonic acids are analogues of natural 
a-amino acids. This invention is also relates to a method for 
controlling tumor invasion, treating inflammation and con-
trolling blood coagulation in patients using the novel com-
pounds of the present invention. We have found that peptidyl 25 
derivatives of aromatic diesters of aminoalkylphosphonic 
acids are potent inhibitors of chymotrypsin-like enzymes, 
elastases, blood coagulation enzymes, tryptases, kallikreins, 
and therefore they are useful as anti-tumor, anti-
inflammatory and anticoagulant agents. 30 antibodies, enzymes, plasma proteins, tissue extracts or 
other proteins and peptides which are widely sold for use in 
clinical analyses, biomedical research, and for many other 
reasons. 
2. Description of the Related Art 
Serine proteases play critical roles in several physiologi-
cal processes such as digestion, blood coagulation, comple-
ment activation, fibrinolysis, and reproduction. Serine pro- 35 
teases are not only a physiological necessity, but also a 
potential hazard if they are not controlled. Blood coagula-
tion serine proteases are responsible for vascular clotting, 
cerebral infarction and coronary infarction. Chymotrypsin-
like enzymes and plasrnin are involved in tumor invasion, 40 
tissue remodeling, and clot dissociation. Uncontrolled pro-
teolysis by other serine proteases such as elastase may cause 
pancreatitis, emphysema, rheumatoid arthritis, intimation 
and adult respiratory distress syndrome. Accordingly, spe-
cific and selective inhibitors of these proteases should be 45 
potent anticoagulants, anti-inflammatory agents and anti-
tumor agents useful in the treatment of protease-related 
diseases (Powers and Harper, in Proteinase Inhibitors, Bar-
rett and Salvesen, eds., Elsevier, 1986, pp. 55-152; 
Tryggvason, Hoyhtya and Salo, Biochem. Biophys. Acta, 50 
1987, 907, 191-217, incorporated herein by reference). In 
vitro proteolysis by trypsin, chymotrypsin or the elastase 
family is a serious problem in the production, purification, 
isolation, transport or storage of peptides and proteins. 
BRIEF SUMMARY OF THE INVENTION 
It is an object of this invention to define a novel group of 
specific inhibitors for trypsin, elastase, chymotrypsin and 
other serine proteases. Inhibitors are compounds that can 
reduce or eliminate the catalytic activity of the enzyme. 
Trypsin and trypsin-like enzymes normally cleave peptide 
bonds in proteins and peptides where the amino acid residue 
These and other objects are accomplished by the present 
invention which defines novel peptidyl derivative of aryl 
diesters of a-aminoalkylphosphonic acids. These phospho-
nate derivatives are potent inhibitors of serine proteases 
including chymotrypsin-like enzymes, trypsin-like 
enzymes, elastase-like enzymes, and other enzymes with 
other substrate specificities. The phosophonates are stable in 
bu1fer or plamsa, and inhibit the serine proteases to give 
stable inhibited enzyme derivatives. The phosphonates can 
be used both in vitro and in vivo. 
DETAILED DESCRIPI10N OF THE 
INVENTION 
Peptidyl derivatives of aryl diesters of 
a-aminoalkylphosphonic acids have be found to be excel-
lent inhibitors of several serine proteases including bovine 
thrombin, human factor Xlla, human factor Xa, human 
plasma kallikrein, bovine trypsin, rat skin tryptase, human 
leukocyte elastase, porcine pancreatic elastase, bovine 
chymotrypsin, human leukocyte cathepsin G and rat mast 
55 cell protease IL The diesters of cx-aminoalkylphosphonic 
acids are analogues of natural a-amino acids and are desig-
nated by the generally accepted three letter abbreviations for 
the amino acid followed by the superscript P. For example 
diphenyl a-(N-benzyloxycarbonylamino)ethylphosphonate 
60 which is related to alanine is abbreviated as 
Cbz-AlaP(OPh)2 • 
on the carbonyl side of the split bond (P 1 residue) is Lys or 
Arg. Elastase and elastase-like enzymes cleave peptide 
bonds where the P 1 amino acid is Ala, Vat, Ser, Leu and 65 
other similar amino acids. Chymotrypsin and chymotrypsin-
like enzymes hydrolyze peptide bonds where the P 1 amino 
CH3 
Bzl-o-co-NH-bH-P/OPh 
11"-0Ph 
0 
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-continued 
Canpletie Structure of Cbz- AJaP(OPh), 
+ NH2 
Pcptidyl derivatives of aryl diesters of 
a-aminoalkylphosphonic acids inhibit serine proteases by 5 
reaction with the active site serine to form "phosphonylated" 
enzymes, which due to similarity of phosphorus atom to the 
tetrahedral intermediate formed during peptide hydrolysis, 
show rem.table stability. The enzyme catalytic apparatus is 
required to activate the phosphorus atom for nucleophilic 10 
substitution and reaction with enzyme. The activation is 
mainly due to precise interaction with the S 1 pocket of 
various serine proteases. The following figure shows the 
reaction course of a phosophonate with a serine protease. 
The phospbonate first binds to the enzyme (below left) and 15 
then reacts to focm a covalent bond with the active site serine 
residue (below right). Slow aging can take place with loss of 
the pbenoxy group (below center). 
/OPh 
p 
11"-oPh 
0 
RCO-( 4-AmPhGly)"(OPh)2 
RCO-
H 
/OPh 
p 
11"-0Ph 
0 
RC0-(4-AmPbe)P(OPh)2 
Additional specificity as well as increased activation 
toward reaction with the enzyme can be introduced into the 
inhibitor molecule by variation of the amino acid sequence 
in the peptide portion of the structure. In fact there is a good 
agreement between the sequence of enzyme substrates such 
Active Site 
R 
Ser1115 
I 
O-H--·llis57 
I /OPh 
11.-co-NH-CH-P 
11"-0Ph 
0 
> 
Active Site 
Aging> 
oxyanion 
hole 
Active Site 
R I Ser1115 
I ,...o H-Hi6'1 
R-CO-NH-CH-P 
ll'o-
N"_.o ••• H 
I I 
N N 
oxyanion 
hole 
20 as a peptidyl p-nitroanilides and the sequence of an effective 
peptidyl phosphonate inhibitor. The best inhibitors have the 
sequence of the best peptidyl p-nitroanilide substrate for a 
particular enzyme. For example, the best inhibitor for chy-
motrypsin and chymotrypsin-like enzymes is Suc-Val-Pro-
25 PheP(OPhh which has an amino acid sequence that is 
analogous to Suc-Val-Pro-Phe-NA, an excellent substrate 
for these enzymes. With human leukocyte elastase, the two 
best inhibitors [MeO-Suc-Ala-Ala-Pro-ValP(OPhh and 
Boc-Val-Pro-ValP(OPh)z] have an amino acid sequence 
30 similar to MeO-Suc-Ala-Ala-Pro-Val-NA and Boc-Val-Pro-
Val-NA, two excellent substrates for this enzyme. For 
bovine thrombin, the best phosphonate inhibitor is diphenyl 
Bo c-D-Ph e-Pro-amin o( 4-amidinoph enyl) 
methanephosphonate hydrochloride, which corresponds to 
35 Boc-D-Phe-Pro-Arg-NA, which is excellent substrate for 
thrombin, and D-Phe-Pro-Arg-H which is an excellent pep-
tide aldehyde inhibitor of thrombin and an anticoagulant 
(Bajusz, S., Szell, E., Bagdy, D., Barabas, E., Horvath, G .• 
Dioszegi, M., Fittier, Z., Szabo, G., Juhasz. A., Tomori, E., 
40 and Szilagyi, G., J. Med. Chem. 33, 1729-1735 (1990) 
inooiporated by reference). Since good substrate sequences 
are known in the literature for other serine proteases, it is 
possible to predict the structure of additional excellent 
phosphonate inhibitors for .these enzymes [Mammalian 
45 Proteases, A Glossary and Bibliography, Vol. 1 
Endopeptidases, Academic Press, Barrett, A. J., and 
McDonald, J. K. eds, pp. 1-416, 1980; Mammalian 
Proteases, A Glossary and Bibliography, Vol. 2 
E;wpeptidases, Academic Press, Barrett, A. J., and 
Peptides with a C-tcnninal phosphonate residue which is so McDonald, J. K. eds, pp. 1-357, 1986; Lottenberg, R., 
an analog of valine [e.g. Val"(0Ph)
2
] arc potent and specific Christensen, U., Jackson, C. M., and Coleman, P. L., Meth-
iacvcrsiblc inhibitors of clastasc and elastase-like enzymes. ods in Enzymology 80, 341-361 (1981) the preceding 
articles are incorporated herein by reference]. It is also 
The peptides with C-tcrminal phosphonate residues related possible to design good phosophonate inhibitors for serine 
to phenylalanine, other aromatic amino acids oc amino acids 
with long aliphatic side chains are potent and specific 55 proteases based on on the peptide sequences found in other 
inhibitors of cbymotrypsin and chymotrypsin-like enzymes. potent reversible and irreversible inhibitors for those same 
serine proteases reported in the literature [Powers and 
The peptides with C-tcrminal phosphonate residues related Harper, in Proteinase Inhibitors, Barrett and Salvesen. eds., 
to ornithinc. lysine, arginine oc containing a C-terminal 
di h l f · (4 'd' h I) Elsevier,1986,pp.55-152;Trainor,D.A.,TrendsinPhann. p eny ester o a-ammo-a- -am1 mop eny S . 8 30,, 3 (Y7 ( 1987) th din arti" 1 · mcthan~phonatc [(4-AmPhGl f(OPh) l or a-amino- 60 c1. , :---' v, e prece g c es are mcorpo-
"'I"""" Y 2 rated herem by reference]. 
a-( 4-amidinophenylmcthyl)mcthanephosphonate [ ( 4-
AmPhe f (OPhhl are specific and potent inhibitors of 
trypsin and trypsin-like enzymes. 
Examples of phosphonate inhibitors for various enzymes 
are given below: 
5,686,419 
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Cbz-Gly--Leu---PheP(OZ), for catbepsin G and RMCP II 
MeO-Suc-Ala-Ala-Pro---Met"(OZh for Cathepsin G 
Suc--Pro--Leu--PheP(OZh and Boc-Ala-Ala~(OZ):, for RMCP I 
Boc--Oly--Leu---PheP(OZ),, Suc-Phe--Leu-Pbe"(OZ):, for human and dog skin chymase 
Boc-Ala-Ala--Ohl(OZh for S. aureus V-8 protease 
Cbz--Oly--O!y--Pro"(OZ):, for human prolyl endopeptidase 
Ala--Pro"(OZ), for DPP IV 
Suc-Ala-Ala-Pro---VaJP(OZ):, for PPE 
Suc--Lys(Cbz)--Val-Pro---ValP(OZ):,, for human leukocyte (neutrophil) elastase 
adamantyl-SO,,---Lys(COCH2CH2C02H)-Ala-ValP(OZh, 
adamantyl..cH2CH20CO--Olu(O-t-Bu)-Pro---ValP(OZ):,, 
adamantyl-S02--Lys(CO-CJ14C02H)-Ala-v..JP(OZ):, 
Suc-Ala-Ala-Pro---Leu"(OZ):, 
Glu-Pbe-X and Dns--Ala--Phe-X 
D-Val--Oly-X and Dns--Olu--Gly-X 
Cbz-Pbe-X and CBz-Trp---X 
Cbz-Lys-X 
Cbz--Oly-X 
for elasrolytic proteinase from "Schistosoma monsoni" 
for plasmin 
for fa::tor Xa 
for porcine pancieatic and human plasma killikreins 
for human skin tryptase 
for human lung tryptase 
6 
Cbz-Ilc-Ala--Oly-X 
Glu--Gly-X 
for factors IXa, Xa, Xia, Xlla and bovine plasma kallikrein 
for urokinase 
DD&-Phe---Pro-X 
DD&-Ile-Pro---X 
Cbz-Trp---X 
Cbz--Oly-X 
Cbz-Pbe-X 
Cbz-Phe--Oly-X 
for plasminogcn activator 
for activated protein C 
for bovine factor IXa 
for bovine factor Xa and Xia 
for bovine factor Xlla 
for trypein 
25 
where Z represents an aryl group, a substituted aryl group or 
a highly fluorinated alkyl group and X represents 
Arg"(OZh, OrnP(OZh, LysP(OZh, an aryl diester of 
a-amino-a-(4-amidinophenyl)methanephosphonate 
[abbreviated NH2-CH(AmPh)PO(OZ)z or 4-AmPhGlyP 30 (OZ)z], or a-amino-a-(4-amidinophenylmethyl) 
methanephosphonate [abbreviated NH2-CH(AmPhCHJPO 
(OZ)2 or 4-AmPhe(OZ)z]. 
described previously (Bartlett et al., Bioorg. Chem., 1986, 
14, 356-377 incorporated by reference). 
The synthesis of AmPhe(OPh)z derivatives is illustrated 
in the following figure. 
The inhibitory potency of peptidyl derivatives of aryl 
diesters of a-aminoalkylphosphonic acids is also determined 35 
by the electronic property of the Z group. More electron 
withdrawing groups such as nitro, cyano, halogen, etc. on 
the aryl ring can make the phosphorus atom in the inhibitor 
more electrophilic and accelerate reaction with the active 
site serine of the serine protease. Reactivity toward serine 40 
proteases can also be obtained by using derivatives where 
the Z groups are highly fluorinated alkyl groups. However 
increased reactivity can also result in low chemical stability 
and in extreme cases, compounds may be too hydrolytically 
unstable for practical purposes if the Z group is too elec- 45 
tronegative. Phosphonates where the Z group is not suffi-
ciently electron withdrawing will be chemically very stable 
and will react very slowly with serine proteases or not at all. 
Such non-reactive inhibitors would include derivatives 
where Z is simple alkyl groups (e.g. peptidyl derivatives of 50 
alkyl diesters of a-aminoalkylphosphonic acids). Thus the 
phosphonate ester groups (Z) should represent a balance 
between these two competing factors and we find that 
diphenyl esters (Z=Ph) are one way to obtain a balance 
between increased reactivity and stability in solution. 55 
Diphenyl esters of a-aminoalkylphosphonate can be syn-
thesized by a previously described method (Ole.ksyszyn et 
al., 1979, Synthesis, 985 incorporated by reference). 
Di(substituted phenyl)esters of a-aminoalkylphosphonate 
can also be prepared by the same procedure using tris 60 
(substituted phenyl) phosphite instead of triphenyl phos-
phite. Perfluoroalkyl diesters can be synthesized by a 
method involving transesterification (Szewczyk et at., 
Synthesis, 1982, 409-414 incorporated by reference). 
Alternatively, the synthesis of diesters of 65 
a-aminoalkylphosphonic acids and their peptides can be 
performed by esterification of the phosphonic acid moiety as 
CN 
n.~NH, + ¢ +P(OA>b ~ 
CHO 
CN 
OPh 
p/ 
o? '-oPh 
Z-(4-AmPhGly)"(OPh)2 
RCO-
H 
H-( 4-AmPhGly)"(OPh)2.HCI 
OPh 
p/ 
11'-oPh 
0 
Peptide derivatives of 4-amidinophenylglycine phospho-
nate diphenyl ester were prepared using the reactions outline 
in scheme shown above. The parent compound Z-( 4-
AmPhGlyt(OPh)2 was prepared by a-amidoalkylation of 
triphenyl phosphite with 4-cyanobenzaldehyde ·and benzyl 
carbamate (60°-90° C., AcOH, 2 h) to give 
5,686,419 
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Z-(4-CN-PhGlyf(OPhh (70%) which was converted to the 
iminoester (dry HCI in CHCIJethanol) and then to the 
amidine derivative Z-(4-AmPhGlyf(OPhh (dry NH3 in 
methanol, 7~0%). Hydrogenolysis of Z-(4-AmPhGlyf 
(0Ph)2 save H-(4-AmPhGlyf(OPh)2 (60-80%) which was 5 
then coupled respectively with Z-Pro-OH, Boc-D-Phe-Pro-
8 
OH, and 2-NpS02-Gly-OH using CDI to give Z-Pro-(4- or a pharmaceutically acceptable salt, wherein: 
AmPhGlyf(OPhh, Boc-D-Phe-Pro-(4-AmPhGlyf(OPhh R is selected from the group consisting of phenyl substi-
(29%) and 2-NpS02-Gly-(4-AmPhGlyf(OPh)2 (30%). tuted with B, benzyl substituted with Bon the phenyl ring, 
Deblockina gave D-Pbe-Pro-(4-AmPhGly)P(OPhh (24%). to and C1....s alkyl substituted with B, 
The 4-amidinophenylalanine phosphonate dipheliyl ester B is selected from the group consisting of amidino 
derivative Z-(4-AmPhef(OPhh was synthesized from [-C(=NH)NH2], guanidino -NH-C(=NH)NH21. 
4-cyanophenylacctaldchyde using the same reaction scheme isothiureido [-S-C(=NH)NH2], and amino, 
with sliptly modified conditions (a-amidoalkylation, Zand Z1 are the same or different and are selected from 
50-' 0%) H dr 1 · 1s the group consisting of C1....s pedluoroalkyl, phenyl, phenyl 25-35%; amidination sequence, 7 . y ogeno ysts substituted with J, phenyl disubstituted with J, and phenyl 
produced H-(4-Am.Phe)P(OPhh (85-90%) which was trisubstituted with J, 
coupled with Boc-D-Phe-Pro-OH to give Boc-D-Phe-Pro- J is selected from the group consisting of halogen, C1--<S 
(4-AmPhef(OPh)2 (59%). Z-Pro-(4-AmPhef(OPhh was alkyl, Ci....s pedluoroalkyl, C1....s alkoxy, N02, CN, OH, 
obtained as a transeste:rification product during the amidi- C02H, amino, C1....s alkylamino, C2-12 dialkylamino, C1--<S 
nation of Z-A-o-(4-CN-Phef(OPhh (50%). Deblocking of 20 acyl, Ci....s alk.oxy-CO-, and C1--<S alkyl-S-, 
with dry HCI/CHC13 produced D-Phe-Pro-(4-AmPhe)P AA4, AA3, and AA2 are the same or different and are 
(OPhh (80%). selected from the group consisting of 
The dipbenyl phospbonate moiety is very resistent to (a) a single bond, and 
chemical hydrolysis and at pH 7 .5 we did not observe any 25 (b) a blocked or unblocked amino acid residue with the L 
hydrolysis after several days (monitored by 31P NMR). or D configuration at the a-carbon selected from the 
Furthermore. they show excellent stability in human plasma. group consisting of alanine, valine, leucine, isoleucine, 
For example Suc-Val-Pro-~(OPhh has a hydrolysis half- proline, methionine, methionine sulfoxide, 
time in human plasma of about 20 hrs. These experiments phenylalanine, tryptophan, serine, threonine, cysteine, 
demonstrate that the phosphonate inhibitors are remarkably 30 tyrosine, asparagine, glutamine. aspartic acid, glutamic 
stable in buffer and plasma. Thus they can be used under a acid, lysine, arginine, histidine, phenylglycine, 
variety of conditions. Phosphonates have the additional norleucine, norvaline, alpha-aminobutyric acid, 
advantage of being very stable in plasma and will have a citrulline, hydroxyproline, ornithine, and 
high effectiveness in vivo due to their long lifetimes. homoarginine, and 
Additionally, the inlubitor-enzyme complex is very stable 3S (c) glycine, sarcosine, epsilon-aminocaproic acid, and 
and the enzyme did not regain any activity after several beta-alanine. 
hours in the case of chymotrypsin and after several days no x is selected from the group consisting of H, NH2-
recovcry of activity was observed in the the cases of CO-, NH2-CS-, NH2-S02-, y -NH-CO-, 
clastases and trypsin. These experiments show that it is NH-SO Y-CS- Y-SO d Y-NH-CS-, Y- 2-, , 2-, possible to decrease or eliminate the enzyme activity an Y--0--CO--, Y-CO-, and Y-CO--, 
biological function of serine proteases for extended time 40 y is selected from the group consisting of C1....s alkyl, C1--<S 
periods. :tluoroalkyl, C1--<S alkyl substituted with K, C1--<S :tluoroalkyl Either racemic mixtures of the diphenyl substituted with K, 9-:tluorenylmethyl, phenyl, phenyl sub-
a-aminoaltylphosphonate residue or pure diastereomers can stituted with J, phenyl disubstituted with J, phenyl trisub-
be used in the inlubitcr structures. The racemic compounds 45 stituted with J, naphthyl, naphthyl substituted with J, naph-
are more easily synthesized and are obtained from less thyl disubstituted with J, naphthyl trisubstituted with J, C1....s 
expensive starting materials. The pure optically active alkyl with an attached phenyl group, C1....s alkyl with two 
a.-aminoalkylpbospbonate derivatives required in the syn- attached phenyl groups, cl-6 alkyl with an attached phenyl 
thesis are more difficult to synthesize (Kafarski et at .• Can. group substituted with J, and C1--<S alkyl with two attached J. Chem. 1983, 61, 2425) and require more expensive so phenyl groups substituted with J, and 
starting IDltc:rials. In the case of the peptidyl phosphonate K is selected from the group consisting of halogen, 
inhibitors which are mixtures of two diastereomers, only one COOH, OH, CN, N02, NH2 , C1--<S alkoxy, C1....s alkylamine, 
will usually react with the enzymes. The pure diastereomers C 1_6 dialkylamine, C1_6 alkyl-0-CO-, C1-6 
will possess higher inlubition rates and could be used at alkyl--0--CO--NH, and C1....s alkyl-S-. 
lower concentrations. ss The blocking groups which may be present on -HN-
P e p tidy l derivatives of aryl diesters of CH(R)-P(O)- or on the amino acidAA4, AA3, andAA2 
a-aminoalkylpbosphonates may be used in vivo to treat are those well known in the art of peptide synthesis. For 
diseases resulting from abnormal or uncontrolled blood example, a listing of suitable peptide blocking groups is 
coagulation or diseases caused by uncontrolled iroteolysis found in Gross et al., eds. The Peptides, Vol. 3 (Academic 
by elastase, chymotrypsin, trypsin and related serine pro- 60 Press, New York, 1981). The particular choice of the block-
teases. These inlubitors may be used in vitro to prevent ing group used in the compounds of the invention depends 
iroteolysis which occurs in the process of the production, on several factors, including the blocking group's affect on 
isolation, purification, storage or transport of peptides and enzyme specificity, its affect on phosphonate solubility, and 
irotcins. its utility during synthesis. Suitable blocking groups include 
The novel peptidyl derivatives of aryl diesters 65 but are not limited to carboberizyloxy (Cbz), benzoyl, 
a-aminoalky]phosphonates of the present invention have the t-butyloxycarbonyl (Boe), glutaryl, p-tolylsulfonyl (Tos), 
following structural fcrmula: methoxysuccinyl (MeO-Suc), and succinyl. 
5,686,419 
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The -HN--CH(R)-P(O)- residue is derived from a 
blocked or unblocked alpha amino acid residue -HN--CH 
(R)--CO- whose alpha carbonyl group has been replaced 
10 
(Powers, J. C. and Oleksyszyn, J., abstract to the FASEB 
meeting, May 1988, Las Vegas). It is not obvious from the 
abstract that peptide phosphonate derivatives could be 
designed based on the peptide inhibitors and peptide sub-by a P(O) group. The R group is the side chain of the alpha 
amino acid. The alpha amino acid residue is derived from 
natural alpha amino acids such as those listed in the IlJPAC-
IlJB Joint Commision on Biochemical Nomenclature report 
on the Nomenclature and Symbolism for Amino Acids and 
Peptides (J. Biol Chem., 260, 14-42 (1985) incoxporated by 
reference). The choice of the particular amino acid residue 
used in the design of the phosphonate inhibitor will depend 
on the enzyme targeted for inhibition. For example, with 
chymotrypsin-like enzymes which prefer Trp, Tyr, or Phe at 
the P1 position of their substrates, -TrpP-, ¥-,and PheP-
residues would be suitable phosphonate residues to incor-
porate into the P 1 position of an inhibitor. With elastase-like 
enzymes which prefer Vat, Ser, or Ala at the P 1 position of 
their substrates, -ValP-, Ser-, and AlaP-residues would be 
suitable phosphonate residues to incorporate in the P 1 posi-
tion of an inhibitor. Likewise with trypsin-like enzyme 
-LysP- or -Ar~-residues would be suitable. Unnatural 
blocked or unblocked alpha amino acid residues can also be 
used in the design of phosphonate inhibitors. If the target 
serine protease will hydrolyze a substrate containing the 
unnatural amino acid residue at the P1 position or if an 
inhibitor structure contains the unnatural amino acid residue 
as the P 1 residue, then this residue can be used in the design 
s strates for many serine proteases, and would be inhibitors for 
many serine proteases. In particular, in this invention we 
now find that Cbz-Phe-Pro-PheP(OPh)2 is a potent inhibitor 
of cathepsin G and rat mast cell protease Il (two other serine 
proteases). Many other examples are given in the tables. It 
10 is not obvious from the abstract that the stereochemistry of 
the phosphonate will affect the inhibitory potency. Thus, 
MeO-Suc-Ala-Ala-Pro-ValP(OPhh obtained by a better 
synthetic route is a better inhibitor of human leukocyte 
elastase and porcine pancreatic elastase due to the presence 
15 of a higher concentrations of the reactive stereoisomer. It is 
not obvious from the abstract that many different amino acid 
residues can be used in the design of phosphonate inhibitors. 
It is not obvious from the abstract that phosphonates can be 
designed for all serine proteases using peptides of varying 
20 length and with varying amino acid residues. It is not 
obvious from the abstract how to design phosphonates for 
elastase, chymotrypsin or any serine protease from peptide 
inhibitor and peptide substrate sequences. 
The following compounds are representative of but do not 
25 limit the invention: 
of a phosphonate inhibitor. For example, chymotrypsin 
hydrolyzes para-tluorophenylalanine containing substrates 
and thus the -HN--CH(CH2C6H4F)-P(O)- and -HN- 30 
would be suitable for incoroporating into a chymotrypsin 
inhibitor. Likewise, trypsin will hydrolyze substrates with 
aminoethylcysteine residues and cathespin G will hydrolyze 
aminopropylcysteine residues and thus -HN-CH 
(CH 2SCH 2CH 2NH 2)-P(O)- and -HN-CH 35 
(CH2SCH2CH2CH2NH2)-P(O)- would respectively be 
suitable residues to incorporate into inhibitors for trypsin 
and cathepsin G. One skilled in the art of designing inhibi-
tors for proteolytic enzyme can list many other unnatural 
amino acid residues which could be used in the design of 40 
suitable inhibitors. 
Other aryl diesters of a-aminoalkylphosphonic acids have 
been prepared earlier for other purposes (illustrative 
examples: Oleksyszyn, J. et al., Synthesis, 1979, 985-986.; 
Vo-Quang, Y. et al., J. Med. Chem. 1986, 43, 579-581.; 45 
Kafarski, P. et al., Tetrahedron, 1987, 43, 799-803.; 
Szewczyk, J. et al., Synthesis, 1982, 409-414; the preceding 
articles are incorporated herein by reference). 
A few other derivatives of cx-aminoalkylphosphonic acids 
have been prepared recently for inhibition of serine 50 
proteases, but they are not peptidyl derivatives or are pep-
tidyl derivatives with the phosphonic acid moiety inside the 
peptide chain (Bartlett et al., Bioorg. Chem., 1986, 14, 
356-377.; Lamden et al., Biochem. Biophys. Res. 
Commun., 1983, 112, 1085-1090; the preceding articles are 55 
incorporated herein by reference). We have published some 
of our work in a paper "Irreversible Inhibition of Serine 
Proteases by Peptidyl Derivatives of 
cx-Aminoalkylphosphonate Diphenyl Esters", Oleksyszyn 
and Powers, Biochem. Biophys. Res. Commun. 161, 60 
143-149 (May 30, 1989 issue). Subsequently, Fastrez et al., 
Tetrahedron Lett., 1989, 30, 6861--6864 reported phospho-
nate inhibitors similar to those which we reported and which 
we describe in this specification (both the preceding articles 
are incorporated herein by reference). Two peptidyl phos- 65 
phonate derivatives, Cbz-Phe-Pro-PheP(OPhh and MeO-
Suc-Ala-Ala-Pro-ValP(OPhh were reported by us earlier 
Diphenyl amino(4-amidinophenyl)methane-phosphonate 
dihydrochloride [abbreviated NHrCH(Am-C6H4)PO 
(0Ph)2 or (4-AmPhGlyl(OPhhl 
Diphenyl N-benzyloxycarbonylamino( 4-amidinophenyl) 
methanephosphonate hydrochloride [abbreviated Cbz-NH-
CH(Am-C6H4)P0(0Phh, or Cbz-(4-ArnPhGlyl(OPhhl 
Diphenyl N-(N-benzyloxycarbonylprolyl)amino( 4-
amidinophenyl)methanephosphonate hydrochloride 
[abbreviated Cbz-NH-Pro-NHCH(Am-C6H4)PO(OPhh or 
Cbz-Pro-(4-ArnPhGlyl(OPh)i] 
Diphenyl N-(D-Phe-Pro )amino( 4-amidinophenyl) 
methanephosphonate dihydrochloride [abbreviated D-Phe-
Pro-NHCH(Am-C6H4)P0(0Ph)2 or D-Phe-Pro-( 4-
AmPhGiyt(OPhhl 
Diphenyl N-(Boc-D-Phe-Pro )amino( 4-amidinophenyl) 
methanephosphonate hydrochloride [abbreviated Boc-D-
Phe-Pro-NHCH(Am-C6H4)P0(0Phh or Boc-D-Phe-L-Pro-
(4-AmPhGlyf (OPh)~ 
Di phenyl N-(N-~-napthylsulfonylglycyl)amino( 4-
amidinophenyl)methanephosphonate hydrochloride 
[abbreviated naphthylsulfonyl-Gly-NHCH(Am-C6H4)PO 
(0Ph)2 or 2-NpS02-Gly-(4-AmPhGly)P(OPhh] 
Cbz-AlaP(OCH2CF3h 
Cbz-PheP(OCH2CF3h 
Cbz-ValP( 4-F-C6H40h 
Cbz-MeiP(OPhh 
Cbz-Met(Ol(OPh)2 
MeiP(OPh)2.HBr 
Cbz-NHCH(4-N02-C6HJP0(0Ph)2 
Benzoyl-NHCH(4-NH2-C6H4)PO(OPh)2 
Cbz-NHCH(4-CN-C6H4)P0(0Phh 
NH2CH( 4-N02-C6H4)P0(0Phh 
Cbz-NHCH(CH2=CH-)P0(0Phh 
Cbz-NHCH(4-C02H-C6H4)P0(0Phh 
Cbz-NHCH(3-CHrC6H4)P0(0Phh 
CF3CF2CF2CO-AlaP(OPhh 
ProP(OPh)2.HCl 
(m-Tos-Phe)-C~4CO-ValP(0Phh 
Cbz-Ala-AlaP(OPhh 
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Cbz-Ala-Phe1'(0Ph)z in the prevention and inhibition of edema and granuloma 
Cbz-Ala-Vat'(OPh}i tissue formation as shown in Table m by effective inhibition 
Cbz-~Vat'(OPh)z of the proteolytic function of human leukocyte elastase. 
Inactivation rates of serine proteases by aryl diesters of Cbz-~Phe1'(0Ph)z 5 peptidyl derivatives of a-aminoalkylphosphonates were 
Cbz-Phc-Phe1'(0Ph)z measured by the incubation method. An aliquot of inhibitor 
Cbz-Lcu-Phe1'(0Ph)z (25 or 50 µ1) in Me2SO was added to a buffered enzyme 
Cbz-Val-Phe1'(0Ph)2 solution (0.01-2.3 µM) to initiate the inactivation. Aliquots 
·- ,p ( 50 µl) were withdrawn at various intervals and the residual Cbz-Val-Var (OPh)z 
10 enzymatic activity was measured.· Me2SO concentration in Cbz-~Vat'(4-F-CJI.O)z the reaction mixture was 8-12% (v/v). A O.lM HEPES, 
Cbz-~Phe1'(0CH2CF3)z O.OlM CaC12 , pH 7.5 buffer was utilized for trypsin and Cbz-~Vat'(OEt)z trypsin-like enzymes. A O.lM HEPES, 0.5M NaCl, pH 7.5, 
Boc-~Phe1'(0Ph)z was utilized for the other serine proteases. The inhibitor 
Boc-~Vat'(OPh)z 15 concentrations are shown in the Tables I, II, Ill, and N. 
Peptide thioesters or peptide nitroanilides with the appro-Boc-~NvaP( OPh)z priate sequences were used as substrates for various serine 
Ala-AJaP(OPh)2.HBr proteases. All peptide thioesters hydrolysis rates were mea-
Ala-Pro"(OPh)z.HCl sured with the assay mixture containing 4,4'-
Phe-AlaP(OPh)z.CF3COOH 20 dithiodipyridine [e324=19800 M-1cm1 ; Grasetti & Murray, 
P Arch. Biochem. Biophys. 1967, 119, 41-48]. Peptide Cbz-Ala-Ala-Val (OPhh 
4-nitroanilide hydrolysis was measured at 410 nm [e41o= 
Cbz-Phc-Pro-PheP(OPhh 8800 M-1cm-1; Erlanger et al., Arch. Biochem. Biophys. 
Cbz-Val-Val-ValP(OPh)z 1961, 95, 271-278]. First order inactivation rate constants 
Cbz-Phc-Pro-PheP(OPhh 25 (k:.,o,) were obtained from plots of ln vfv0 vs time, and the 
Suc-Phe-~Phe1'(0Ph)z correlation coefficients were greater then 0.98. 
Suc-Val-~Phe1'(0Ph)2 Table V shows the prothrombin time of pig plasma measured in the presence of_ various inhibitors. Diphenyl Boc-Val-~Vat'(OPh)z N-benzyloxycarbonylamino( 4-amidinophenyl) 
Boc-Ala-~ValP(OPh)2 30 methanephosphonate hydrochloride can prolong the clotting 
McO-Suc-Ala-Ala-~M~(OPh)z time from 17.7 to 25.2 sec. Compounds 
McO-Suc-Ala-Ala-~Mct(O)"(OPh)z Cbz-(4-AmPhGly)"(OPh)z, Boc-D-Phe-Pro-(4-AmPhGly)" 
McO-Suc-Ala-Ala-Ala-ValP(OPh)z (0Ph)2 , D-Phe-Pro-(4-AmPhGlyf(OPh)z, and D-Phe-Pro-
(4-AmPhe)P(OPh)z were tested in human plasma with the 
McO-Suc-Ala-Ala-Ala-NvaP(OPh)z 35 prothrombin (PT) and activated partial thromboplastin time 
McO-Suc-Ala-Ala-Ala-PheP(OPh)z (APIT) coagulant assays and the Pf was prolonged from 
Mc0-Suc-Ala-Ala-~ValP(OPh)2 14.6 see to 17.0. 19.8, 29.3, and 28.0 sec in the presence of 
Mc0-Suc-Ala-Ala-~Phe1'(0Ph)z 125 µM of Cbz-(4-AmPhGly)"(OPh)z, D-Phe-Pro-(4-
McO-Suc-Ala-Ala-~LcuP(OPh)z AmPhGly)"(OPh)z, D-Phe-Pro-(4-AmPhe)"(OPh)z, and 63 
40 µM of Boc-D-Phe-Pro-(4-AmPhGlyf(OPh)i, respectively. McO-Suc-Ala-Ala-~NvaP(OPh)z At the same inhibitor concentrations, the APfT was pro-
Cbz-(4-CN-Phef(OPh)z longed from 34.0 sec to 61.2, 73.0 106, and >140 sec, 
4-CN-PheP(OPh)z.HBr respectively for Cbz-(4-AmPhGly)"(OPh)z, D-Phe-Pro-(4-
Cbz-(4-AmPhef(OPh)z AmPhGly)"(OPh)z, D-Phe-Pro-(4-AmPhe)"(OPh)z, and 
(4-AmPhcf(OPh)z.2HCl 45 Boc-D-Phe-Pro-(4-ArnPhGly)"(OPhh- Both compounds 
"' Boc-D-Phe-Pro-(4-ArnPhGly)"(OPh)2 and D-Phe-Pro-(4-
Cbz-Pro-(4-CN-PheJ (OPh)z AmPhef(OPh)2 prolonged the Pf ca. 2 fold and prolonged 
Cbz-Pro-(4-AmPhe)"(OEt)z the APIT ca. 3-4 fold although their thrombin inhibition 
Boc-D-Phe-Pro-(4-CN-Phe)"(OPh)z rates differed by over 200 fold. 
Boc-D-Phe-Pro-(4-AmPhe)"(OPh)z 50 Anticoagulants can prolong the clotting time of human 
D-Phe-Pro-(4-AmPhe)"(OPh)z plasma and play important roles in the treatment of blood 
Boc-Phc-Phe-(4-AmPhGly)"(OPh)z coagulation related diseases such as vascular clotting, cere-
Cbz-Tbr-(4-AmPhGlyf(OPh)z bral infarction and coronary infarction (Williams et al., 
Hematology, 3rd ed. McGraw Hill, 1983 and Ingram et al., 
Boc-Lcu-Thr-(4-AmPhGlyf(OPh)z 55 Bleeding Disorders, 2nd ed. Blackwell Scientific 
(4-AmPbGly)P(OPh-4-Cl)z, and Publications, 1985). These two books are incorporated 
Z-(4-AmPhGlyf (0Ph-4-Cl)2• herein by reference. The presence of certain inhibitors of this 
It has been found that compounds of the present invention invention in the human plasma would prolong the prothrom-
have anticoagulant activity as shown in Table I, Table II, and bin time, thus these inhibitors would act as anticoagulant in 
Table V by effective inhibition of the proteolytic function of 60 vivo. Currently, there are a few anticoagulant drugs in use 
blood coagulation enzymes in Hepes buffer and in pig clinically, and the inhibitors described in this invention can 
plasma. It bas also been found that compounds of the present be used as anticoagulants in the treatment of animals. 
invention have anti-twnor activity as shown in Table I, Table It is known that the in vitro activity of elastase inhibitors 
Il. Table m, and Table N by effective inlubition of the correlates with their in vivo activity in animal models of 
proteolytic function of trypsin-like, elastase-like and 65 emphysema and inflammation (Otterness et al., editor, 
cbymotrypsin-lik:e enzymes. Compounds of the present Advances in Inflammation Research, Vol 11. Raven Press 
invention have anti-inflammatory activity and are effective 1986, and this book is incorporated herein by reference). 
5,686,419 
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Thus the novel inhibitors listed in Table m will be useful for 
the treatment of emphysema and intimation. Elastase inhibi-
tors have been used orally, by injection or by instillation in 
the lungs in animal studies [Powers, Am. Rev. Respir. Dis., 
127, 54-58 (1983); Powers and Bengali, Am. Rev. Respir. 
Dis. 134, 1097-1100 (1986) and these two articles are 
incorporated herein by reference]. The inhibitors described 
above can be used by any of these routes. 
The activity of some proteases correlate directly with the 
invasiveness of tumor cells [Nakajima, M. et al., Science, 
1983, 220, 611-613; Sloane, B. F. et al., Cancer Res. 1982, 
42, 980-987 and these two articles are incorporated herein 
by reference]. The tumor invasion can be stopped by treat-
ment with inhibitors of serine proteases [Thyggvason, K. et 
al., Biochem. Biophys. Acta, 1987, 907, 191-217, and this 
article is incorporated herein by reference]. Thus the novel 
inhibitors showed in Table I, Table TI, Table ill, and Table N 
will be useful for treatment of tumors. 
For treatment of blood coagulation-related diseases, 
tumor invasion or inflammation, the compounds of the 
present invention may be administered orally, topically or 
parenterally. The term parenteral as used includes subcuta-
neous injection, intravenous, intramuscular, intrasternal 
injection or infusion techniques. The pharmaceutical com-
positions containing the active ingredient may be in the form 
suitable for oral use, for example as tablets, troches, 
5 
14 
lozenges, aqueous or oily suspension, dispersible powders or 
granules, emulsions, hard or soft capsules or syrups or 
elixirs. Dosage levels of the order to 0.2 mg to 140 mg per 
kilogram of body weight per day are useful in the treatment 
of above-indicated conditions (10 mg to 7 gms per patient 
per day). The amount of active ingredient that may be 
combined with carrier materials to produce a single dosage 
form will vary depending upon the host treated and the 
10 particular mode of administration. 
15 
To use the above inhibitors in vitro, they are dissolved in 
an organic solvent such as di.methylsulfoxide or ethanol, and 
are added to an aqueous solution containing serine pro-
teases. The final concentration of organic solvent should be 
less than 25%. The inhibitors may also be added as solids or 
in suspension. The serine protease inhibitors of this inven-
tion would be useful in a variety of experimental procedures 
where proteolysis is a significant problem. Inclusion of these 
20 inhibitors in radi.oimmunoassay experiments would result in 
higher sensitivity. The use of these inlubitors in plasma 
fractionation procedures would result in higher yields of 
valuable plasma proteins and would make purification of the 
proteins easier. The inhibitors disclosed here could be used 
25 in cloning experiments utilizing bacterial cultures, yeast, and 
cell lines. The purified cloned product would be obtained in 
higher yield. 
TABLE I 
Rates of Inhibition of Trypsin-like Serine Protease by Peptidyl Derivatives of Dipbenyl cx-Amino-
(4-Amidinopbenyl'!methanephosphonate•. 
&i.i!l!l!M:'s-1) 
bovine bovine hwnan human plasma rat skin 
Inhibitor trypsinb thrombin factor XIIa kallikrein tryptase0 
Cbz-NH-CH(Am-CJ14)PO(OPh), 2,000 170 20 18,000 94 
Cbz-Pro--NH-CH(Am-CJl.)PO(OPh):, 100 70 2.6 59 NI" 
D-Phe-Pro--NH-CH(Am-CJf.)PO(OPh), 110 730 2.8 250 NI 
Boc-D-Phe-Pro--NH-CH(Am-CJl.)PO(OPh), 2,200 12,300 52 (,() NI 
Naphthylsulfonyl-Oly-NH-CH(Am-CJl4 )PO(OPh):, 470 170 25 %0 16 
"Enzyme (0.06-2.3 µM) was incubated with inhibitor (1.66-106 µM) in 0.25--0.6 ml of 0.1 M Hepes, O.Ql M CaCJ.,, pH 7.5, 
8-12% Me,SO at 25° C. Aliquots (50-150 µL) were withdrawn at various intervals and the residual enzymatic activity measured 
as previously described. Residual activity was measured with Z-Arg--SBzl (80 µM). The k,,.,... values were calculated from plots 
of ln v/v 0 vs time. · 
bResidual activity of trypsin was assayed with Z--Phe----Oly-Arg-NA ( 122 µM). 
0 Rat skin tryptase was assayed in 25 mM NaH2P04 , 1 mM EDTA, 0.5 M NaCl, pH 7.5 buffer. 
dNI, less than 5% of inhibition was obtained after 30 min. 
TABLE II 
Rates of Inhibition of Thrombin and Other Trypsin-like Serine Proteases by Peptide Phosphonate Derivatives 
of 4-Amin<xlinimpbenylglycine and 4-Amidinophenylalanine• 
~l!li:M:'s-'! 
lruman bovine human human plasma bovine 
Inhibitor thrombin tbrombin fuctor XIla kallikrein trypsin 
Cbz-(4-AmPhGlyf(OPh):, 80 170 20 18,000 2,000 
Cbz-Pro-(4-AmPhGlyf(OPh), 20 70 2.6 (,() 100 
Boc-D-Phe-Pro-(4-AmPhGlyf(OPh), 11,000 12,000 52 l(i() 2,200 
D-Phe-Pro-(4-AmPhGlyf(OPh), 700 730 2.8 250 110 
2-NpS02----0ly-(4-AmPhGlyf(OPh)2 170 25 %0 470 
Cbz-( 4-AmPhef (OPh), 0.2 24 
H-(4-AmPhe f(OPh), 2.2 32 
5,686,419 
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TABLE II-continued 
llUea of lahibition of 'Ibrombin md Other Trypsin-like Serine Proteases by Peptide Phospbonate Derivatives 
of 4-Amim!jniprn2;nyWycjpe md 4-Amidinopbenylalanine" 
human bovine human human plasma bovine 
Jnbibitor tbrombin tbrombin facior Xlla kallibein trypsin 
NI 
0.7 
54 
NI 
130 
50 
"EllZymrl (O.D3-2.3 µM) was incubated with the inhibitor (1.7-420 µM) in 0.3--0.6 mL of 0.1 M Hepes, O.Ql M 
CaCI, (0.5M N.Cl fur human tbrombin), pH 7 .5, 8-12% Me,SO at 25° C.Aliquots (25--150 µL) were witb:irawn 
at varioul iatern.la md the -idual enzymatic activity were measwed. Residual activity of trypsin and other 
cmplatioll mizymes ....., -yed with Z-Pbc--Oly-Arg-NA (100-120 µM) and Z-Arg-SBzl (80#µM), 
~ely. The t._.. ve- - calculated from pseudo first-Older plots. 
TABLE ill 
RD COllllallts fur Inactivation of Serine Protease by Peptides with C-Tenninal Ary! 
Diestms of !l;-AminoollkviDbo!!l!bonates". 
ChY!!!211'VllSin• PPEC HIE' 
[I] k,.,.l[I) [I) k.....l[Il [I) k.,..J[I] 
lmctivatol' (µM) (M"'s-') (µM) (M"'s-') (µM) (M"'s-') 
Cb2---P!o-Val"(OPh), 8.2 NI 10 20 5.3 130 
Cbz--Pro-.l'beP(OPh), 8.2 230 8.2 NI" 4.3 20%f 
Cbz-Ala--Ala--VaiP(OPh), 8.2 NI 24.3 340 13.5 1300 
MeO--Suc-Ala--Ala-Pn>--Nvif (OPh), 8.2 50 8.6 4200 95 380 
MeO--Suc-Ala--Ala--Al-Val"(OPh):, 90.1 15 9.1 2800 5 1500 
MeO--Suc-Ala--Ala--Al-Phe'(OPh):, 5.3 12,000 105 NI 58 NI 
MeO--Suc-Ala--Aia-Pn>--Val"(OPh), 180 21 9 9,100 49 10,100 
MeO--Suc-Ala--~(OPh), 26 1,500 26 740 14.4 140 
MeO--Suc-Ala--Aia-Pn>-Pbe"(OPh):, 11 11,000 100 NI 50 NI 
MeO-Suc-Ala--Aia-Pn>--Met"(OPh), 30 570 30 44 76 53 
Boc-V.J.-...Pio--Val"(OPh), 8.2 NI 8.7 11,000 4.5 27,000 
Cbz--Pbe--l'lo--l'(OPh)z 4.6 17,000 92 NI 8.2 NI 
Suc-Val--l'ro--Pbe'(OPh)z 5.5 44,000 8.2 NI 4.1 NI 
Cbz-Pbe"(OPh), 55 21 
Cbz-Val"(4-F-C.,H.O), 230 0.7 30 77 
Cbz-Pl<r-Va!Pf.4-F~O), 150 13.8 150 36 
'Coidltiolll were u follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 al 25° C. Rate constants were obtained as 
ct.cribed hebe. 
'Bnzyme CIOlll:elllrati 1.6 µM. 
"l!myme ccucemation 1.8 µM. 
'l!myme CIOlll:elllrati 0.32 µM. 
"NJ, leu liml 5% of inhibitioo WU obtained after 1 hr. 
'20% of inhibition was obWDed initially md the inhibition was mt time dependent. 
TABLEN 
Rate COOlllants ~I)) fDr Inactivation of Cathespin G, md Rat Mast Cell Protease Il by Peptidyl 
Derivative! of Dipbeuyl !l;.(N-l!enzyioxvcubonyl).2-pbenyl.ethylphosphonate•. 
Cathe!!l!in a• RMCPII" 
lnactMlor [I) (µM) k..,.l[I] (M"1s-1 ) [I] (µM) k.....l[I) (M-•s-') 
Cbz-f'heP(OPh), 82 76 82 89 
MeO--Sec-Ala--Ala--Ala--Phe'(OPh):, 13.6 370 170 6.8 
MeO-Suc-Ala-Ala--Pro--Pbe•(oPb), 13.1 440 130 39 
Cbz--Pbe--l'lo--l(OPh), 5.1 5,100 5.1 32 
Suc-Val--l'ro--Pbe'(OPh), 8.4 36,000 3 15,000 
"!nactivabaa rues wae measured by incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7 .5 buffer, containing 9% 
Jde,SO and at 25° C. Enzyme cooceolration were: cathespin G, 1.6 µM; RMCP Il, 38 nM. 
'catbelpin 0 was -yed with Sue-Val-Pro-Pho-Na (0.5 mM). 
"RMCP II WM -yed with Suc-Ala--Ala-Pro---Pbe-Szl (88 µM) in the presence cxl 4,4'-ditbiopyridine (0.33 
mM). 
16 
17 
TABLEV 
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Diphenyl N-benzyloxyearbonylamino( 4-amidinophenyl)-
methanephosphonate hydrochloride [Cbz-(4-AmPhGlyl 
(OPhhl. A solution of 7 g diphenyl 
N-benzyloxycarbonylamino( 4-cy anophenyl)-Effect of Peptidyl Derivatives of Diary I Esters of 
a-Amiooa!kylpOOsphonates on PI and APIT in Pig Plasma•. 
[I] PI AP1T 
Compouals (µM) (sec) (sec) 
Control 0 18.6 17.7 
Cbz-NH--CH(Am-C.sll.)PO(OPh):, 32 21.3 25.2 
5 methanephosphonate in 150 ml of dry chloroform and 15 ml 
of absolute ethanol was saturated with dry HCl at 0° C. The 
mixture was kept in the refrigerator until 1LC (thin layer 
chromatography) showed the absence of starting material 
(about 24 hrs). An excess of pentane was added and the 
Boc-D-P~NH--CH(Am- 16 
C.sll.)PO(OPh):, 
D-Phe--Pro---NH-CH(Am-CJi4)PO(OPh):, 32 
•Average of two trials 
18.8 
19.1 
18.8 
19.7 
10 precipitated solid was removed by filtration and dried using 
a vacuum line. The solid was dissolved in 200 ml of dry 
methanol and gaseous dry ammonia was passed through the 
solution (one equivalent is required) for about 20 min. 
Methanol and excess ammonia was removed quickly on a 
15 rotary evaporator. A 100 ml portion of fresh methanol was 
TABLE VI 
Half-Lives for Dephosphonylation of Serine Proteases 
Inactivated by Diphenyl c;-Amiooalkylphosphonates Derivatives". 
added and solution was heated at 50° C. for about 8 hrs until 
the 1LC shows the absence of imino ether. The solvent was 
evaporated and the resulting oil was dissolved in chloro-
form. Addition of ether caused the oil to solidify. After 
__ _..!Jt,.1:1.a..i.CHrs.......,> ___ 20 filtration the resulting solid was again dissolved in 
Chymo-
Inactivator trypsin 
Cbz-vat•(OPh):, 
PPE 
<48 
m:.E 
<48 
chloroform, the solution was filtered and the solid was 
precipitated by addition of ether. In several experiments, the 
yields were 70-80%; mp.154°-158° C. (decomp); 31PNMR 
14.87 ppm. Anal. Calcd. for C28H270 5 N3 ClP.0.3 Cbz-Pro-VaJP(OPh):, 
Cbz-Ala-Ala-Val•(OPh):, 
MeO-Suc-Ala-Ala--Pro-ValP(OPh):, 
<48 <48 
<48 
<48 <48 
25 NH4Cl.H20: C, 57.41; H, 5.16; N, 7.52; Cl, 7.31. Found: C, 
57.75; H, 5.00; N, 8.86; Cl, 7.43 
Cbz-Phe•(OPh):, lo" 
MeO-Suc-Ala-Ala--Pro--Phe"(OPh):, 16 
Cbz-Pbe-Pro--Phe"(OPh):, 26 
MeO-Suc-Ala-Ala-Ala-Ph?(OPh), 10 
Suc-Val--Pro-PheP(OPh):, 7.5 
"Enzy hne activity was measured after removal of excess of inhibitors as 
described previously. 
An improved amidination procedure was also developed 
subsequently and should be used in future syntheses. The 
imino ester is dissolved in a fleshly prepared solution of 
30 ammonia (1.5 eq.) in methanol, ammonium chloride (1 eq.) 
is added, and the mixture is then stirred at r.t for 1 day. 
b About 50% of reactivation was obtained after 10 hrs, but oo further progress 
observed even after 48 hrs. 
35 The following examples are given to illustrate the inven-
tion and are not intended to limit it in any manner. 
General Synthesis Procedures 
Benzyl carbamate, triphenyl phosphite, 40 
4-cyanobenzaldehyde, 1,1'-carbonyldiimidazole (CDI), 1,3-
d.icyclohexylcarbodiimide (DCC), and all common chemi-
cals were obtained from the Aldrich Co., Milwaukee, Wis. 
Blocked amino acid derivatives were obtained from Aldrich 
or Bachem Bioscience Inc., Philadelphia, Pa. The NMR 45 
spectra were recorded on a Varian Gemini 300 MHz instru-
ment 31P NMR spectra were obtained at 161.895 MHz 
using broad band 1H decoupling on a Varian XL-400 instru-
ment; chemical shifts were rep<rted relative to 85% phos-
phoric acid (sealed capillary) at 0.000 ppm with positive 50 
values downfield. Elemental analyses were performed by 
Atlantic Microlabs of Atlanta, Ga. 
EXAMPLE 1 
Diphenyl N-benzyloxycarbonylamino(4-cyanophenyl) 55 
methanephosphonate [Cbz-(4-CN-PhGlyl(OPh)2] was 
obtained from 9.75 g of 4-cyanobenzaldehyde, 7.65 g of 
benzyl carbamate and 13.5 ml of triphenyl phosphite in 20 
ml of glacial acetic acid, according to the synthetic proce-
dure described earlier (Oleksyszyn J., Subotkowska L., 60 
Mastalerz P., Synthesis, 1979, 985). Yield 70%; top. 
135°-138° C.; Anal. Calcd. for C28H2305N~.!12 H20: C, 
66.27; H, 4.73; N, 5.52. Found: C, 66.03; H, 4.51; N, 5.49. 
Cbz-NHCH(4-N02-C6H4)P0(0Phh and Cbz-NHCH(3-
Me-C6H4)P0(0Phh with m.p. of 151°-153° C. and 65 
127°-129° C. respectively were obtained by the same pro-
cedure using the corresponding benzaldehyde. 
EXAMPLE2 
Cbz-ValP(4-F-C6H40h. Tris(4-fiuorophenyl) phosphite 
was prepared by a previously described method (Walsh, J. 
Am. Chem. Soc. 1959, 81, 3023-3031). Cbz-ValP(4-F-
C6H40)2 was obtained from 6.8 ml of isobutyraldehyde 
(0.075 mole), 7.65 g benzyl carbamate (0.05 mole) and 18.2 
g of tris(4-fiuorophenyl) phosphite in 10 ml of glacial acetic 
acid as described in example 1, mp. 94 °-96° C. Anal. Calcd. 
for C24H24N05PF2: C, 60.63; H, 5.05; N, 2.95. Found C, 
60.84; H, 5.11; N, 2.90. 
Cbz-AlaP(4-Me-C6H40h, Cbz-AlaP(4-Cl-C6H40h, 
Cbz-AlaP(3,4-dichloro-C6H30b Cbz-AlaP(4-F-CJ140h, 
Cbz-ValP(4-Me-C 6H40)2, Cbz-ValP (3,4-dimethyl-
C6H30h, Cbz-PheP( 4-F-C6H30h, Cbz-PheP(3,4-dimethyl-
C6H30h can be prepared by the same procedure using the 
corresponding tris(substituted-phenyl) phosphite and the 
corresponding aldehyde. 
In general, Cbz-NH-CH(R}-P(OXOZ)(OZ1) can be 
prepared by reaction of R--CHO with P(OZ)(OZ1)(0Z2). 
EXAMPLE3 
Diphenyl amino( 4-amid.inophenyl)methanephosphonate 
dihydrochloride [(4-AmPhGiy)1'(0Phh]. A sample of 1.8 g 
of diphenyl N-benzyloxycarbonylamino(4-amidinophenyl) 
methanephosphonate hydrochloride was dissolved in 150 ml 
of 2N HCl methanol solution and after addition of 5% Pd/C 
catalyst, the solution was stirred under an atmosphere of 
hydrogen until the theoretical amount of hydrogen was 
consumed. The catalyst was removed by filtration and after 
evaporation of the methanol, the residue was crystallized 
from ethanol-ether. In several experiments, the yields were 
60-80%; mp. 213°-215° C.; Anal. Calcd. for 
C2oli22N3ClP.Yl H20: C,51.85; H, 4.97; N, 9.08; Cl, 15.34. 
Found: C, 51.73; H, 5.02; N, 9.10; Cl, 15.36. 
5,686,419 
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AlaP(4-F-CJI.-0h.H0, ValP(4-Me-C6H40h.HO, PheP 
(4-0-CJI.-0)2.HO can be prepared by the same procedure. 
In general, NH2-CH(R)-P(O)(OZ)(OZ1) hydrochlo-
ride can be prepared from Cbz-NH--CH(R)--P(O)(OZ) 
(OZ1) using the same procedure. This intermediate can then 5 
be used to prepare a great variety of derivatives by reaction 
with acylating agents. carbamylating agents, sulfonylating 
agents, chlcrofo.rmatcs, or by coupling with a variety of 
peptides and blocked peptides using standing peptide cou-
pling reactions, many of which are illustrated in the follow- 10 
ing examples. 
20 
L-Pro-OBzl (2.42 g) were coupled using DCC, and Boc-D-
Phe-Pro-OBzl was obtained in 83% yield; 1 H NMR (CDC13) 
07.34 (s, 5H), 7.23 (m, 5H), 5.4 (d, lH), 5.15 (q, 2H), 4.65 
(m, lH), 4.35 (m, lH), 3.5 (m, lH), 3.1-2.9 (m, 2H), 2.6 (m, 
lH), 2.-1.7 (m, 4H), 1.43 (s, 9H). 
Hydrogenolysis was performed in methanol with 5% 
water using 5% Pd/Casa catalyst. The product Boc-D-Phe-
Pro-OH was obtained as a whim solid and recrystallized 
from aqueous methanol, yield 85%, mp 173°-174° C.; 1H 
NMR (DMSO) 07.3-7.15 (m, 5H), 7.0 (d, lH), 4.45(m, lH), 
4.10 (m, lH), 3.6-2.7 (m, 4H), 2.2-1.6 (m, 4H), 1.30 (s, 9H); 
MS (FAB+) m/e 363 (M+l); [o:]20 D=-91.5° (0.14 g/rnL in 
methanol). Anal. (C19H2t;N"20 5) C, H, N. 
Diphenyl N-(N-benzyloxycarbonylprolyl)amino( 4-
amidinopbcnyl)mcthancphosphonate hydrochloride [ Cbz-
Pro-( 4-AmPhGly )P ( OPh hJ. To 0.5 g (2 mmol) of 
N-bcnzyloxycarbonylprolinc in 3 ml of DMF at 0° C., 0.45 15 
g (2.77 mmol) of CDI was added and the reaction mixture 
was stirred at D° C. for 1 hr. Then 0.9 g (2 mmol) of diphenyl 
amino(4-amidinopbenyl)methanephosphonate hydrochlo-
ride was added. After stirring by 18 hrs at 0°-5° C., 10 ml 
of water was added. The oil which precipitated was washed 
with water and solidified by washing with a cold O.lN 
solution of HO. One gram of compound was obtained which 
was used without purification in the next step. 31P NMR 
12.31, 12.62 (free base) and 15.11, 15.41 ppm 
(hydrochlcridc). After addition of one drop concentrated 25 
HO to the NMR tube, 14.22, 14.54 ppm (ratio 1:1). 
To 0.36 g (1.0 mmol) of Boc-D-Phe-Pro-OH in 2 ml of 
dry DMF at 0° C., 0.17 g ( 1.05 mmol) of CDI was added. 
After stirring for 1 hr at 0° C., 0.45 g (1.0 mmol) of 
dihydrochloride of diphenyl amino(4-amidinophenyl) 
methanephosphonate was added and the solution was stirred 
for48 hrs at 0° C. Water ( 10 ml) was added and the oil which 
20 precipitated out was decanted and washed with distilled 
water. The oil was dissolved in chloroform and the solution 
was washed with 4% NaHC03, water, and 0.05N HCl. After 
drying over MgS04, the solvent was removed and the 
Benzoyl-Ala-ValP(OPhh, Formyl-Ala-ValP(OPhb 
Fmoc-Ala-ValP(OPh) 2 [Fmoc, 
9-fluorcnylmcthyloxycarbonyl]. PhNHCO-Ala-ValP(OPhh, 30 
PhNHCS-Ala-ValP(OPhh. Dansyl-Ala-ValP(OPh)2. Tosyl-
Ala-ValP(OPhh, Trityl-Ala-ValP (OPhh, Phthaloyl-Ala-
Val"(OPh)i, Cbz-Pro-AlaP(4-F-CJI40h, Cbz-Pro-ValP(4-
Mc-CJI..Oh, Cbz-Pro-ValP(3-0-C6H40h, Cbz-Pro-PheP 
(4-0-CJI.-Oh, Cbz-Pro-Ph?(4-F-CJI40h, Cbz-Ala-ValP 35 (3-Me-CJI.-O)i, Cbz-Ala-PheP(3,4-dichloro-C6H30h can 
ireparcd by the same procedure by coupling with the 
appropiatc blocked amino acid or amino acid derivative. 
EXAMPLE4 
Diphenyl N-(D-Phe-Pro )amino( 4-amidinophenyl)-
methanephosphonate dihydrochloride. One gram of deriva-
tive obtained in the ircvious experiment was hydrogenated 
40 
in lN solution of HO in methanol with 0.1 g 5% Pd/C, until 
the the<nti.cal amount of hydrogen was consumed. After 45 
filtration of the catalyst and evaporation of the solvent, the 
resulting oil was dried using a vacuum line. A 0.9 g (1.64 
mmol) sample of the product dihydrochloride was added to 
a solution of 0.43 g (1.64 mmol) of Boc-D-Phe and 0.34 g 
(2 mmol) of DCI in 2 ml dry DMF, which was allowed to 50 
react for 1 hrs at 0° C. After 24 hrs 10 ml of water was added 
and the oil which irccipitatcd was decanted. After washing 
with O.lN HO, the oil which solidified was separated by 
filtration ud dried using a vacuum line. The dry solid was 
dissolved in 1N HO solution in methanol and solution was 55 
stirred by 1 hr. Solvent was removed on a rotary evaporator 
and the oil was dried using a vacuum line by several hours 
to give 0.3 g of iroduct Yield 24%; mp. 220°-224° C.; 31P 
NMR. 16.95, 17.25. 17,60 ppm (stereoisomers and 
conformers). Anal. Calcd. for C:wH380,N2CIP.5H20: C, 60 
51.78; H, 6.09; N, 8.88; 0, 9.00; Found; C, 51.21; H, 5.95; 
N. 9.04; 0. 8.97. 
EXAMPLES 
Diphenyl N-(Boc-D-Phe-Pro )amino( 4-amidinophenyl)- 65 
methanephosphonate hydrochloride [Boc-D-Phe-L-Pro-( 4-
AmPhGlyf (OPh)z]. Boc-D-Phc-OH (2.66 g, 10 mole) and 
resulting oil was dried on a vacuum line for a few hours to 
give 0.22 g of product. Yield 29%; mp. 185°-190° C.; 31p 
NMR, 12.42, 12.66, 12.79 ppm (stereoisomers and 
conformers) (free base); 15.12, 15.38, 15.58 
(hydrochloride). Anal. Calcd. for C3gll450 7 N ,CIP. ¥2H20: C, 
60.75; H, 5.97; N, 9.08; 0, 4.60. Found: C, 60.98; H, 6.48; 
N, 8.26; Cl., 4.26. 
Tosyl-D-Phe-Pro-ArgP(OPh)i, Cbz-D-Phe-Pro-ArgP 
(OPh)z, Boc-D-Phe-Pro-Art'(OPh)i, Boc-D-Phe-Pro-OrnP 
(OPhh, Boc-D-Phe-Pro-Art'(4-F-C6H40)2 , Boc-D-Phe-
Pro-ArgP( 4-Me-C6H40)z, Boc-D-Phe-Pro-ArgP(3.4-
dichloro-C6H30)z, Boc-D-Phe-Pro-Art'(3-Cl-C6H40)z can 
be prepared by the same procedure by coupling with the 
appropriate blocked peptide or peptide derivative. 
EXAMPIE6 
Di phenyl N-(N-~-naphylsulfonylglycyl)amino( 4-
amidinophenyl)methanephosphonate hydrochloride 
[2-NpS02-Gly-(4-AmPhGlyf(OPh)z]. Using the same pro-
cedure as example 5, 0.3 g ( 1.13 mmol) of 
~-naphylsulfonylglycine, 0.2 g ( 1.23 mmol) of CDI and 0.45 
g (1.0 mmol) of diphenyl amino(4-amidinophenyl) 
methanephosphonate dihydrochloride (obtained in Example 
3) were reacted and 0.21 g of product was obtained. Yield 
30%; mp. 205°-210° C. (decomp); 31P NMR, 11.76 ppm 
(free base), 14.74 ppm (hydrochloride). Anal. Calcd. for 
C32H3(i0t;N"4ClPS.H20: C, 56.24; H, 4.69; N, 8.20; S. 4.69. 
Found: C, 56.87; H, 4.43; N, 8.79; S, 5.06. 
EXAMPLE? 
Cbz-Met"(OPh)z. This compound was synthesized by the 
method described in example 1: yield 36%; m.p. 93°-95° C.; 
one spot on TLC, R.f=0.73; 31P NMR 19.68 ppm. Anal. 
Calcd. for C24H260,NSP: C, 61.15; H, 5.52; N, 2.r;J?; S, 
6.79. Found:. C, 61.06; H, 5.60; N, 2.91; S, 6.88. 
Cbz-MetP(4-Cl-C6H40)z, Cbz-Met"(4-Me-C6H40)z, 
Cbz-Met"(3-Me-C6H40)2, Cbz-Met"(4-F-C6H40)z. Cbz-
Met"(3,4-dimethyl-CJI30)z can be prepared by the same 
procedure using corresponding tris( substitutedphenyl) phos-
phite. 
MeO-Suc-Ala-Ala-Pro-Met"(OPh)z. The reaction of 
MeO-Suc~Ala-Ala-Pro-OH (0.64 g, 1.73 mmol), H~-CH 
5,686,419 
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from ethanol-hexane: mp. 197°-200° C.; one spot on TLC, 
Rj=0.63; 31P NMR 19.40, 19.24 ppm, ratio 1:0.72. Anal. 
Calcd. for C3oH410~4P.0.25 Hexane: C, 57.60; H, 6.85; N, 
8.61. Found: C, 57.58; H, 6.62; N, 8.36. 
Cbz-Ala-Ala-Ala-ValP(OPh)2, MeO-Suc-Ala-Ala-Ala-
ValP ( 4-F-C6H40h, CH3NHCO-Ala-Ala-Ala-ValP(OPhh, 
PhNHCS-Ala-Ala-Ala-ValP(OPh)i, Me0-Suc-Ala-Ala-
Ala-Va1P(3-Cl-C6H40h, PhNHCO-Ala-Ala-Ala-ValP(3,4-
dimethyl-C6H30h, MeO-Suc-Ala-Ala-Ala-ValP( 4-Me0-
(CH2CH2SCH3)P(0)(0Ph)i. HBr (0.85 g, 2 mmol), 
obtained from Cbz-Met1'(0Ph)2, N-methylmorpholine (0.2 
ml, 2 mmol) and DCC (0.34 g, 1.73 mmol) under an 
atmosphere of nitrogen gave 0.5 g ( 42 % ) of product as whim 
solid. A 0.2 g sample was purified on preparative TLC under 5 
an atmosphere of nitrogen to give product as a white solid: 
top. 41°-43° C.; one spot on TLC, R_t=0.6; 31P NMR 19.50, 
19.36 ppm, ratio 1: 1.32. Anal. Calcd. for 
C32H430~4PS.THF; C, 56.69; H, 6.69; N, 7.35; S, 4.20. 
Found: C, 57.37; H, 6.77; N, 7.76; S, 4.49. 10 C6H40)2 can be prepared by the same procedure using the 
corresponding tripeptide and diester of a-amino-2-
methylpropylphosphonate. 
MeO-Suc-Ala-Ala-Pro-Met" ( 4-Cl-C6H40)i, Me0-Suc-
Ala-Ala-Pro-Met1'(3-Me-C6H40)2, Me0-Suc-Ala-Ala-Pro-
Met1'(3,4-dimethyl-C~30h can be prepared by the same 
procedure. · 
EXAMPLE 8 
Cbz-Ala-Ala-ValP(OPhh Cbz-Ala-Ala-OH (0.294 g, 1 
mmol) was dissolved in 10 ml of dry THF and cooled to 0° 
15 
EXAMPLE 11 
MeO-Suc-Ala-Ala-Ala-PheP(OPhh. The reaction of 
MeO-Suc-Ala-Ala-Ala-OH (0.345 g, 1 mmol) and diphenyl 
a-amino-2-phenyl-ethylphosphonate (0.353 g, 1 mmol) 
gave 0.35 g (49.1%) of the product which was purified on 
C. Diphenyl a-amino-2-methylpropylphosphonate, (0.305 20 the preparative TLC, as described above. Recrystallization from methanol gave a white solid: top. 207°-210° C.; one 
spot on TLC, Rj=0.69; 31P NMR 19.06, 19.01 ppm, ratio 
1:0.87. Anal. Calcd. for C34H410~4P.MeOH: C, 58.98; H, 
6.32; N, 7.86. Found: C, 58.66; H, 6.08; N, 7.%. 
g, 1 mmol) and DCC (0.203 g, 1 mmol) were added to this 
solution. After stirring for 8 hrs at 0° C. and overnight at 
room temperature, the solution was worked-up as described 
above. Recrystallization from chloroform-pentane gave 
0.182 g (31 %) of crude product. A sample (0.1 g) was 
purified on preparative thin layer chromatography using 
chloroform-methanol (9:1) as eluent. The product was 
recrystallized from ethanol-pentane to give a white solid: 
top. 93°-97° C.; one spot on TLC, Rj=0.71; 31PNMR 19.44, 
19.31 ppm, ratio 1:1.11. Anal. Calcd. for 30 
C;J1360 7N3P.EtOH; C, 61.19; H, 6.69; N, 6.69. 
25 Me0-Suc-Ala-Ala-Ala-Phe(4-Cl-C6H40)2, Me0-Suc-
Ala-Ala-Ala-PheP(4-MeO-C~40h can be prepared by the 
same procedure. 
EXAMPLE 12 
MeO-Suc-Ala-Ala-Pro-ValP(OPhh MeO-Suc-Ala-Ala-
Pro-OH (0.37 g, 1 mmol) was dissolved in 20 ml of dry 
TI-IF and cooled to 0° C. Diphenyl a-amino-2-
methylpropylphosphonate (0.305 g, 1 mmol) and DCC 
(0.203 g, 1 mmol) were added to this solution. After stirring 
for 6 hrs at 0° C. and overnight at room temperature, the 
solution was filtered and 100 ml of ethyl acetate was added. 
The solution was then washed with 10% citric acid, 4% 
sodium bicarbonate and water successively. After drying 
over magnesium sulfate, the solution was filtered, evapo-
Cbz-Ala-Ala-ValP( 4-Cl-C6H40)2, Cbz-Ala-Ala-ValP( 4-
0Me-C6H40h, Cbz-Ala-Ala-ValP(4-F-C~40h, Cbz-Ala-
Ala-PheP(3,4-dimethyl-C6H30h, Cbz-Ala-Ala-NvaP(3,4-
dichloro-C6H30)i, Cbz-Ala-Ala-Met1'(4-Cl-CjjH40)i, 35 
Acetyl-Ala-Ala-ValP(Ophh, CFrCO-Ala-Ala-Val (OPhh, 
Dansyl-Ala-Ala-ValP(OPh)2, Tosyl-Ala-Ala-ValP(Ophh, 
Fmoc-Ala-Ala-ValP(OPhh. PhNHCO-Ala-Ala-ValP(OPhh 
can be prepared by the same procedure by coupling with the 
appropriate blocked peptide or peptide derivative. 40 rated and the residue was dissolved in 10 ml of THF. Trace 
of DCU was removed by filtration and after addition of 3 ml 
of hexane, the solution was allowed to crystallized. After a 
few days the product was removed by filtration and recrys-
tallized from THF-hexane to give 0.2 g (30%) of a white 
EXAMPLE9 
MeO-Suc~Ala-Ala-Ala-NvaP(OPhh The reaction of 
0.345 g (1 mmol) of MeO-Suc-Ala-Ala-Ala-OH and 0.305 
g ( 1 mmol) of diphenyl a-aminobutylphosphonate gave 0.35 
g (55.3%) of product as a white solid. A 0.1 g sample was 
purified on preparative TLC as described above to give the 
product as white solid: mp. 215°-218° C.; one spot on TLC, 
R..t=0.73; 31P NMR 20.02 ppm. Anal. Calcd. for 
C30H410~4P: C, 56.96; H, 6.49; N, 8.86. Found: C, 56.72; 
H, 6.58; N, 8.80. 
45 solid, mp. 83°-86° C.; one spot on TLC, Rj=0.74; 31P NMR 
19.78, 19.60 ppm, ratio 1:2.12. Anal. Calcd. for 
C32H430J>.hexane: C, 61.30; H, 7.66; N, 7.53. Found: C, 
61.04; H, 7.58; N, 7.69. 
50 
PhNHCO-Ala-Ala-Pro-ValP(3-Cl-C6H40h, PhNHCS-
Ala-Ala-Pro-ValP( 4-Cl-C6H40) 2Me0-Suc-Ala-Ala-Pro-
Va1P ( 4-Me-C6H40h can be prepared by the same procedure. 
Acetyl-Ala-Ala-Ala-NvaP(OPhh, Boc-Ala-Ala-Ala-
NvaP(OPhh, Me0-Suc-Ala-Ala-Ala-NvaP(4-Cl-C6H40h, 
MeO-Suc-Ala-Ala-Ala-NvaP<3,4-dimethyl-C6H30)2, MeO- 55 Suc-Ala-Ala-Ala-NvaP(4-F-C~40)i, Me0-Suc-Ala-Ala-
Ala-Nv~(3-Cl-C6H40h can be prepared by the same pro-
cedure using the corresponding tripeptide and diester of 
a-aminobutylphosphonate. 
EXAMPLE 13 
MeO-Suc-Ala-Ala-Pro-LeuP(OPhh. The reaction of 
MeO-Suc-Ala-Ala-Pro-OH (0.37 g, 1 mmol) and diphenyl 
a-amino-3-methylbutylphosphonate (0.32 g. 1 mmol) gave 
0.38 g (50.1%) of product as white solid: mp. 60°-64° C.; 
one spot on TLC, R,-=0.67; 31PNMR 20.7 L 20.54 ppm, ratio 
EXAMPLE 10 60 
1:1.33. Anal. Calcd. for C33H450~4P.hexane: C, 61.74; H, 
7.78; N, 7.38. Found: C, 61.04; H, 7.53; N, 7.59. 
Me0-Suc-Ala-Ala-Ala-ValP(OPh)2. The reaction of 
MeO-Suc-Ala-Ala-Ala-OH (0.345 g, 1 mmol) and diphenyl 
a-amino-2-methylpropylphosphonate (0.305 g, 1 mmol) 
gave 0.3 g (47.5%) of product as white solid.AO.lg sample 65 
was purified on preparative TLC as described above to give 
the product as a white solid, which was then recrystallized 
EXAMPLE 14 
MeO-Suc-Ala-Ala-Pro-PheP(OPhh. The reaction of 
MeO-Suc-Ala-Ala-Pro-OH (0.37 g, 1 mmol) and diphenyl 
a-amino-2-phenylethylphosphonate (0.35 g, 1 mmol) gave 
0.4 g (50.5%) of product as a white solid: top. 53°-56° C.; 
5,686,419 
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one spot on 1LC, Rj=0.7; 31P NMR 19.41, 19.10 ppm, ratio 
1:2.47. Anal. Calcd. for ~6H430siN"4P.hexane: C, 63.62; H, 
7.19; N, 7.<17. Found: C, 63.42; H, 7.19; N, 7.57. 
24 
hydrogenolysis of Cbz-Pro-PheP(OPh)2 (0.584 g, 1 mmol) 
gave an oil which was dissolved in 30 ml of ethyl acetate. 
To this solution, 0.1 g (1 mmol) of succinic anhydride and 
0.1gof5% Pd/C were added and mixture was stirred under EXAMPLE 15 
Cbz-~Val"(OPh):i. Cbz-~OH (0.97 g, 4 mmol) was 
dissolved in 40 ml of dry THF and cooled to 0° C. Diphenyl 
a-amino-2-mcthylJropylphosphonate (1.2 g, 4 mmol) and 
DCC (0.81 g, 4 mmol) were added to this solution. After 
stining for 6 hrs at 0° C. and overnight at room temperature, 
the DCU was removed by filtration and 50 ml of ethyl 
acetate was added. The solution was washed successively 
twice each time with 10% citric acid, water, 4% sodium 
bicarbonse and water. After drying over MgS04, the mix-
ture was filtered, evap<rated and residue was dissolved in 10 
ml of methylene chloride. A trace of DCU was removed by 
filtration and after addition of 30 ml of pentane, the solution 
was allowed to crystallize. After a few days the product was 
filtered and recrystallized from methylene chloride-hexane 
5 atmosphere of hydrogen until the 1LC showed only one new 
spot. Catalyst was removed by filtration and erganic layer 
was washed several times with water. After drying, the 
organic solvent was removed to give 0.45 g (65%) of 
product as a hydroscopic solid: mp. 50°-53° C.; one spot on 
10 1LC, Rj=0.4; 31P NMR 19.75, 19.23 ppm, ratio 1:1. Anal. 
Calcd. for C34H.w03N~.2H20: C, 59.56; H, 6.42. Found: C, 
59.59; H, 6.42. 
Suc-Val-Pro-Phe1'(4-MeS-C~40h, Suc-Val-Pro-Phe1'(4-
Cl-C6H40)z, Suc-Phe-Pro-Phe(OPh)z, Suc-Val-Pro-PheP 
15 (3-F-C6H40)2, Suc-Val-Pro-Phe1'(3,4,5-trichloro-C6H20)i, 
Suc-Val-Pr<>-PheP (2,3,4-fluoro-C6H20)2, Suc-Val-Pro-PheP 
(4-Me-C;.H40)i, Acetyl-Val-Pro-PheP(OPh)2 , CF3-CO-Val-
Pro-Phe (OPh)z can be prepared by the same procedure. 
to give 1.4 g (65%) of a white solid: mp. 123°-127° C.; one 
spoton1LC, R;=0.74; 31PNMR 19.52(broad), 19.51(broad) 20 
ppm. Anal. Cafcd. for C~330~J>: C, 64.87; H, 6.15; N, 
5.22. Found: C, 64.58; H, 6.23; N, 5.34. 
EXAMPLE 18 
Cbz-AlaP(OCH2CF3)2. This compound was obtained by a 
previously described method involving transesterification 
(Szewczyk et al., Synthesis, 1982, 409-414). 10 ml of 
trifiuoroethanol and 0.46 g of Na (0.02 mole) were mixed 
first, then 4.11 g of Cbz-AlaP(OPh)z was added, and the 
mixture was stirred overnight. 3 ml of AcOH was added and 
the solvent was everaporated. The residue was dissolved in 
CHC13 and washed with water, 2N NaOH and water, and 
Boc-Val-~Val"(OPhh- A solution 0.536 g (1 mmol) of 
Cbz-Pro-ValP(0Ph)2 in 50 ml of methanol with 0.1 g 5% 
Pd/C was stirred under atmosphere of hydrogen at room 25 
temperature fer 2 hrs and filtered through celitc. After 
addition of of Boe-Val-OH (0.217 g, 1 mmol) to the filtrate, 
the solvent was removed in vacuo. The residue was dis-
solved in 20 ml of dry THF and 0.2 g of DCC ( 1 mmol) was 
added. The solution was kept at 0° C. for 6 hrs and overnight 
at room temperature. DCU was removed by filtration and the 
crganic layer was washed with water, twice with 4% 
NaHC03, water, twice with 10% citric acid and water. After 
drying over sodium sulfate, the solvent was evaporated and 
the resulting oil was dried at low pressure for a few hours to 
give 0.45 g (72%) of a whim hydroscopic solid: mp. 62°-66° 35 
C.; one spot on 1LC, Rr0.78; 31P NMR 19.64 ppm. Anal. 
Calcd. fer C31 H44°"7N3P.H20: C, 60.10; H, 7.43. Found: C, 
30 dried over MgS04. The solvent was evaporated and the oil 
was obtained, mass spectrum m/e=423 (M+). 
Cbz-PheP(OCH2CF3)i was prepared by the same 
procedure, mp 85°-87° C., mass spectrum m/e=499 (W). 
Cbz-ValP(OCH2CH3)z was also prepared by the same pro-
cedure using ethanol instead of trifuoroethanol. 
EXAMPLE 19 
60.26; H, 7.49. Benzoyl-NHCH(4-NHrC6H4)PO(OPh)i. NH2CH(4-
Boc-Val-~ ValP( 4-F-C6"40)i, PhNHCS-Val-Pro-ValP N02-C6H4)PO(OPh)i.HBr was obtained by deblocking 
(3-Cl-C6H40h, e-Cbz-a-Cbz-Orn-Val-Pro-ValP(4-F- 40 Cbz-NHCH(4-NOrC6H4)PO(OPhh with 30% of HBr/ C6"40)~, Boe-Val-~ ValP(4-Me0-C6H40)2, Tosyl-Val- HOAc, mp. 198°-200° C. The reaction of NH2CH(4-N02-
~VaF(OPb)i can be prepared by the same procedure. C6H4)PO(OPb)i.HBr and benzoyl chloride in the presence 
EXAMPLE 16 ofN-methylmorpholine gave benzoyl-NHCH(4-N02-C6H4) PO(OPh)i, mp. 157°-159° C., mass spectrum m/e=489 
Cbz-~Pbe(OPb)i. The reaction of Cbz-Pro-OH (0.75 45 (W+ 1). Anal. Cale. for C26H21N20J>: C, 63.88; H, 4.30; N, 
g, 3 mmol), diphcnyl a-amino-2-phenylethylphosphonates 5.73. Found: c, 64.05; H, 4.25; N, 5.69. Hydrogenolysis of 
(1.05 g, 3 mmol) and ~C (~.61 g, 3 ~oli gave 0.93 g benzoyl-NHCH(4-N02-C6H4)PO(OPh)z in the presence of (53%) of puduct as white solid: mp. 81 -84 C.; one spot Pd/C catalyst gave the final product, mp. 156°-158° C., 
on 1LC. Rr0.74; 31P NMR 19.54, 19.48, 19.27 and 19.22 mass spectrum mfe=45 8 (M+). Anal. Cale. for 
ppm (diastc:rcomers and confcrm.crs), ratio of diastereomers 50 C26"23N2Q4P: c, 68.12; H, 5.02; N, 6.11. Found: c. 66.87; 
1:1. Anal. Calcd. for C33H330~J>: C, 67.81; H, 5.65; N, H, 5.15; N, 5.01. 
4.79. Found: C, 67.56; H, 5.79; N. 4.72. 
EXAMPLE20 Cbz-Pbc-Pr<>-PhcP(OPb)2. The reaction of Cbz-Pbe-OH 
(0.3 g, 1 mmol) with the hydrogenolysis product of Cbz-~Pbe(OPb)2 (0.58 g, 1 mmol) and DCC (0.2 g, 1 mmol), 55 4-Cyanophenylacetaldehyde. This compound was pre-
gave 0.4 g (54%) of a hydroscopic semi-solid product after pared from 4-cyanobenzaldehyde using a modification of a 
a standard work-up. A 0.2 g sample was purified on pre- procedure previously used in the multi-step synthesis of 
parative 1LC to give the product as a hydroscopic semi- 2-phenylpropanal [Allen, C. F. H.; van Allan, J. Org. Syn. 
solid: one spot 00 1LC, Rj=0.76; 31p NMR 19.67, 19.57, Coll. Vol 3. 733-734 (1955)]. 
19.32, 19.19 and 19.07 ppm (diastereomers and 60 Ethyl 3-(4-cyanophenyl)-2,3-epoxypropionate. Ethyl 
conformers); ratio, 1.0:0.34:0.82:0.73:0.92. Anal. Calcd. for chloroacetate (6.2 g, 50 mmole) and 4-cyanobenzaldehyde 
C42H42o,N~.2H20: C, 65.71; H, 5.99; N, 5.47. Found: C, (6.6 g, 50 mmole) were dissolved in 100 mL dry benzene. 65.62; H, 6.12; N, 5.Z7. Freshly prepared sodiumethoxide solution in absolute etha-
nol ( 1.3 g sodium in 25 mL ethanol) was added and the 
65 mixture was stirred at r.t. for 20 h. Water (100 mL) was 
added with stirring and after several minutes the organic 
layer was separated, washed with water, dried (MgS04), 
EXAMPLE 17 
Suc-Val-Pro-Phe(OPb)i. The reaction of Cbz-Val-OH 
(0.25 g, 1 mmol). DCC (0.2 g. 1 mmol) and the product of 
5,686,419 
25 
filtered, and evaporated to give the desired epoxy product as 
a yellow oil, yield 70-80%; 1 H NMR (CDC13 ) o7 .68 ( d, 2H), 
7.43 (d, 2H), 4.30 (m, 2H), 4.16 (d, lH), 3.48, (d, lH), 1.34 
(t, 3H). 
Sodium 3-( 4-cyanophenyl)-2,3-epoxypropionate. Ethyl 
3-(4-cyanophenyl)-2,3-epoxypropionate (10.9 g, 50 mmole) 
was dissolved in 50 mL absolute ethanol and cooled with an 
ice bath. A freshly prepared sodium ethoxide solution (1.2 g 
sodium in 25 mL ethanol) was added dropwise during a 10 
min period. Dropwise addition of 1 g of water to the stirred 
mixture caused separation of the sodium salt of the epoxy 
compound. The mixture was stirred for 3 h, the salt was 
collected by filtration, washed with 50 mL ethanol and ether 
several times, and dried, yield 75°-85%; 1H NMR (D20) 
07.58 (d, 2H), 733 (d, 2H), 3.93 (d, lH), 3.39 (d, lH). 
A lN HO solution (50 mL, 50 mmole) was added to the 
sodium salt of the epoxy compound (10.6 g, 50 mmol) 
dissolved in 50 mL water. This resulted in the separation of 
26 
2.0 mmole) was dissolved in a mixture of methanol and 
chloroform (1:1, 20 mL). The solution was cooled to 0° C., 
saturated with dry HO, the solution was kept at 5° C. for 48 
h, and then the solvent was evaporated at r.t in vacuo. The 
5 resulting semisolid was treated with 50 mL dry ether, 
filtered, washed with dry ether, and dissolved in 10 mL 
methanol containing 51 mg (3.0 mmole) ammonia. Ammo-
nium chloride (107 mg, 2.0 mmole) was added, the mixture 
was stirred at r.t. for 1 day, the solvent was removed at r.t. 
10 in vacuo and the resulting semisolid was dissolved in 50 mL 
chloroform, filtered, and the filtrate was evaporated to give 
the crude product. The crude product was treated with 50 mL 
dry ether, stirred, and the undissolved solid collected, 
washed with ether and dried to give the amidine product as 
a yellow powder, yield 50-70%; mp>140 (dee); 1H NMR 
15 (DMSO) 09.4-9.2 (d, 4H), 8.25 (d, lH), 7.8 (d, 2H) 7.6 (d, 
2H), 7.38 (m, 5H), 7.3-7.1 (m, lOH), 4.95 (q, 2H), 4.6 (m, 
lH), 3.4-3.1 (m, 2H); MS (FAB+) m/e 530 (M--Cl). Anal. 
(C29H~30,C1P) C, H, N. 
an oil which solidifed after a short time. This material was EXAMPLE 21 
refluxed with 100 mL toluene for 2.5 h to affect decarboxy- 20 Diphenyl 1-Amino-2-( 4-amidinophenyl) 
lation. The organic layer was separated, washed with water, ethanephosphonate [(4-AmPhe)1'(0Phh.2HCl]. The ami-
dried (Na2S04 ), filtered, and evaporated to give dine Cbz-(4-AmPhe)1'(0Ph)2 (1.0 g, 1.76 mmole) was dis-
4-cyanophenylacetaldehyde as a yellow brownish oil which solved in 150 mL methanol containing 2 mmole HCl, a 
solidified after several hours, yield 35-45%. This product is 25 catalyst (0.5 g of 5% Pd/C) was added, and the mixture was 
unstable and was used immediately for next step, otherwise hydrogenated. After hydrogenolysis, the catalyst was 
polymerization occurs. A sample of the crude product was removed by fitration and the filtrate was evaporated to give 
purified by recrystallization from ether-hexane to give white a near whim crystalline product yield 85-90'* · mp> 180 
crystals, mp 63°-65° C.; NMR (CDC13) 09.81 (s, lH), 7.65, (dee.); 1H NMR (DMSO) o9.5-9.J (d, 4H), 9.2-9~0 (m, 3H), 
(d,2H), 7.35 (d, 2H),3.84 (s, 2H); MSm/e 146 (M+l).Anal. 30 7.9-7.1(m,14H), 4.55 (m, lH), 3.2-3.5 (m, 2H); MS (FAB+) (CgH7N0.0.5H20) C, H, N. m/e 396 (M+l-2HC1). Anal. (C21H24N30 3Cl2P) C, H, N. 
Diphenyl l-(N-Benzyloxycarbonylamino)-2-(4- EXAMPLE 22 
cyanophenyl)ethanephosphonate 
[Cbz-(4-CN-Phe)1'(0Phh]. This compound was synthesized Diphenyl 1-(N-Benzyloxycarbonyl-L-prolyl)amino-2-(4-
from crude 4-cyanophenylacetaldehyde, benzyl carbamate, 35 cyanophenyl)ethanephosphonate [Cbz-Pro-(4-CN-Phe)P 
and triphenylphosphite using a modification of the previ- (OPhhJ. To a cooled solution of the phosphonate 4-CN-
ously described amidoalkylation procedure.9 Benzyl car- PheP(OPhhHBr (0.41 g, 0.9 mmole) and Cbz-Pro-OH 
bamate (6.1 g, 40 mmole) and 4-cyanophenylacetaldehyde (0.25 g, 1.0 mmole) in 20 mL CH2Cl2 was added 0.14 mL 
(4.7 g, 32 mmole) were dissolved in 50 mL toluene and Methyl amine. After stirring for 10 min, DCC (0.21 g, 1.0 
refluxed for 1 h. The toluene was evaporated, glacial acetic mmole) was added and the mixture was stirred at 0° C. for 
acid (10 mL) and triphenyl phosphite (8.5 mL, 32 mmole) 40 2 hand atr.t for 24 h. During this period, dicyclohexylurea 
were added to the residue, and the mixture was heated at 80° (DCU) formed, was removed by filtration and the filtrate 
C. for 2 h. The volatile materials were removed by evapo- was evaporated. The residue was dissolved in 50 mL ethyl 
ration in vacuo and the resulting oil was dissolved in 50 mL acetate, filtered, the filtrate was washed with 50 mL IN HCl, 
methanol. The solution was refrigerated overnight and the water, 6% NaHC03 , and water. The organic layer was dried, 
white precipitate was filtered, dried, and recrystallized from 45 filtered, and evaporated to give crude product which was 
50 mL hot methanol. The undissolved product was then recrystallized from ether to give white crystals, yield 
discarded, and the filtrate was cooled down to give white 52% (0.29 g); mp 131°-132° C.; 1H NMR (DMSO) 08.75 
crystals, yield 25-35%; mp 136°-137° C.; 1H NMR (m, lH), 7.8-7.2(m, 19H), 5.06 (m, 2H), 4.95 (m, lH), 4.6 
(DMSO) 0820 (d, lH), 7.75 (d, 2H), 7.54 (d, 2H), 7.35 (m, 
50 (q, lH), 4.2 (m, lH), 3.5-3.1(m,3H), 2.0-1.4 (m, 4H); MS 5H), 7.3-7.1 (m, lOH), 4.95 (q, 2H), 4.60 (m, lH), 3.4-3.0 (FAB+) m/e 610 (M+l). Anal. (C34H3 :iN30.,P) C, H, N. 
(m, 2H); MS (FAB+) m/e 513 (m+l). Anal. (C2~2sN20sP) EXAMPLE 23 
C,H,N. 
Diethyl l-(N-benzyloxycarbonyl-L-prolyl)amino-2-( 4-
amidinophenyl)ethanephosphonate [ Cbz-Pro-( 4-AmPhe )1' 
(OEth, 10]. This compound was obtained during the amidi-
nation procedure of dipeptide Cbz-Pro-(4-CN-Phe)P(OPhh 
when ethanol was used instead of methanol. Transesterifi-
cation occurred and the phenyl groups were replaced by 
ethyl groups, yield 50% (0.11 g); mp>130° C. (dee); 1H 
Diphenyl 1-Amino-2-( 4-cyanophenyl)ethanephosphonate 
Hydrobromide [4-CN-PheP(OPhbHBr]. Cbz-(4-CNPhe)1' 55 
(OPhh (0.57 g, 1.1 mmole) was mixed with 1.0 mL 30% 
HBr in acetic acid. The mixture was protected against 
moisture and kept at r. t for 1 h. Addition of 50 mL dry ether 
and stirring for several hours resulted in formation of a 
yellow brownish solid which was filtered, washed with 
ether, and dried to give the product (0.48 g, 95%); mp 
197°-199° C.; 1H NMR (DMSO) o9.0 (b, 3H), 7.85 (d, 2H), 
7.65 (d, 2H), 7.4-7.0 (m, lOH), 4.7 (m, lH), 3.4 (m, 2H); MS 
(FAB+) m/e 379 (M-Br). 
60 NMR (DMSO) 09.4-9.2 (m, 4H), 8.4 (m, lH), 7.8-7.1 (m, 
9H), 5.0 (s, 2H), 4.5 (m, lH), 4.2 (m, lH), 4.0 (m, 4H), 
3.5-2.9 (m, 4H), 2.1-1.4 (m, 4H), 1.25 (m, 6H); MS (FAB+) 
m/e 531 (M-Cl). Anal. (C2JI3~406CIP) C, H, N. 
Diphenyl 1-(N-Benzyloxycarbonylamino)-2-(4- 65 
amidinophenyl)ethanephosphonate 
[Cbz-(4-AmPhe)1'(0PhhJ. Cbz-(4-CNPhe)1'(0Phh (1.03 g, 
EXAMPLE24 
Diphenyl l-(N-t-Butyloxycarbonyl-D-phenylalanyl-L-
prolyl)amino-2-(4-cyanophenyl)ethanephosphonate [Boe-
5,686,419 
27 
D-Phe-Iro-(4-CN-Phef(OPhh]. The phosphonate 4-CN-
Phe"(OPhh_HBr (0.46 g, 1 mmole) was coupled with Boc-
D-Phe-PrlH>H (0.36 g, 1.0 mmole) using DCC. The product 
was obtained as a glass-like solid, yield 86% (0.62 g); mp 
85°-90° C.; 1H NMR (DMSO) 08.25 (2d, lH), 7.8-7.0 (m, 5 
19H), 4.8 (m, lH). 4.4 (m, lH), 43 (m, lH). 4.2 (m, lH), 
3.5-2.8 (m, 4H), 2.0-1.4 (m, 4H), 1.3 (m, 9H); MS (FAB+) 
m/e 723 (M+l). Anal. (C..wli4~407P.0.25 H20) C,H,N. 
28 
What is claimed is: 
1. A compound of the formula: 
EXAMPLE24 
or a pharmaceutically acceptable salt, wherein: 
10 R is selected from the group consisting of phenyl substi-
Diphenyl 1-[(N-t-Butyloxycarbonyl-D-phenyWanyl-L-
proly !)amino ]-2-( 4-amidinophenyl)ethanephosphonate 
[Boc-D-Phe-Pro-(4-AmPhef(OPhh]. CDI (0.13 g, 0.8 
mmole) was added to Boc-D-Phe-Pro-OH (0.24 g, 0.67 15 
mmole) in 2 mL DMF. A solution of amidinc (4-AmPhef 
(0Ph):i.2HO (0.31g,0.67 mmole) in 2 mL DMF was added 
to a cooled solution (00 C.) of the peptide and the mixture 
was incubated at 0° C. for 2 h and r.t. for 48 h. DMF was 
removed in vacuo and the residue oil was dissolved in 100 20 
mL CHq,, filtered, and the organic layer was washed 
subsequently with 50 mL 0.05M HCI, 10% KCl, 6% 
NaHC03 • and water. The organic layer was dried, filtered, 
and evaporated to give a crystalline product which was then 
dried in vacuo, yield 59% (0.31g);mp145°-155° C. (dee.); 25 
1H NMR (DMSO) ol0.1-9.7 (m, H), 9.4-9.0 (m, 3H), 
8.0-7.0 (m, 19H), 6.75 (m, lH). 4.9-4.0 (m, 3H), 3.5-2.6 (m, 
6H), 2.0-1.4 (m, 4H). 1.3 (s, 9H); MS (FAB~ m/e 740 
(M-0). Anal. (C..off4~,07P.0.3HC1.1.5H20) C, H, N. 
30 
EXAMPLE25 
Diphenyl 1-(N-(D-Phenylalanyl-L-prolyl)amino-2-(4-
amidinophenyl)ethanephosphonate Dihydrochloride 
[D-Phe-Pro-( 4-AmPhe )P ( OPh) 2 ] • B oc-D-Phe-Pro-( 4- 35 
AmPbef(OPh)2 (0.11 g) was dissolved in 2 mL CH03 and 
the solution was saturated with dry HCI. An oily precipitate 
formed and the mixture was kept at r.t for 2 h before 
evaporating to dryness to obtain the crystalline product, 
yield 80% (0.08 g); mp >165° C. (dee); 1H NMR (DMSO) 40 
a 9.4-9.2 (cl, 4H), 8.5 (m, 3H). 8.2 (m, lH), 7.9-7.0(m, 19H), 
4.8-3.9 (m, 3H), 3.5-2.8 (m, 6H). 2.0-1.1 (m, 4H); MS 
(FAB+) m/e 640 (M+l-20). Exact mass calcd. for 
C3,H~,O,P (M+l-2HO) 640.2689. Found: 640.2786. 
45 
EXAMPLE26 
Boc-Pbe-Phe-(4-AmPhGly)P(OPhh To a THF solution 
(5 ml) of Boc-Phe-Phe-OH (0.21 g, 0.5 mmol) was added 
successively N-methylmorpholine (55 µI, 0.5 mmol) and 50 
isobutyl chloroformate (65 µI. 0.5 mmol) at -15° C. After 
stirring for 2 min and addition of cold THF solution ( 1 ml) 
of triethylamine (70 µI. 0.5 mmol), the mixture was added to 
a DMF s<iution (1 ml) of (4-AmPhGlyf(OPhh.2HCl (0.23 
g, 0.5 mmol) at-15° C. After stirring at-15° C. for 1 hr and 55 
at 0°-5° C. for 12 hr. the reaction mixture was concentrated 
in vacuo. The residue was triturated with ether and was 
purified by chromatography (silica gel, CHO:/CH30H, 
14:1) and solidified from ether to give the final product (80 
mg. 20% yield) as a white powder; mp 149°-170° C .• 60 
Rj=0.45 (CHO:JCH30H/CH3C02H. 80:10:5), Anal. Calcd. 
for C43H470 7N,Cl.H20: C. 62.2; H, 5.95; N, 8.43. Found: 
C, 623; H. 6.01; N. 8.45. 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 65 
spirit of the invention or the scope of the subjoined claims 
and their equivalents. 
tuted with B, benzyl substituted with B on the phenyl 
ring, and C1--6 alkyl substituted with B, 
B is selected from the group consisting of amidino 
{-C(=NH)NH2 }, guanidino {-NH-C(=NH) 
NH2 }, isothiureido {-S-C(=NH)NH2 }, and amino, 
z and Z 1 are the same or different and are selected from 
the group consisting of C1--6 perfluoroalkyl, phenyl, 
phenyl substituted with J, phenyl disubstituted with J, 
and phenyl trisubstituted with J, 
J is selected from the group consisting of halogen, C1--6 
alkyl, C1--6 perfluoroalkyl, C1--6 alkoxy, N02 , CN, OH, 
C02H, amino, C1--6 alkylamino, C2_12 dialkylamino, 
C 1--6 acyl, C1--6 alkoxy-CO-, and C1--6 alkyl-S-, 
AA 2 is selected from the group consisting of 
(a) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, proline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, serine, 
threonine. cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
ornithine, and homoarginine, and 
(b) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, 
AA3 is selected from the group consisting of 
(a) a single bond, and 
(b) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, proline, methionine, methionine 
sulfoxide, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, 
norleucine, norvaline, alpha-aminobutyric acid, 
citrulline, hydroxyproline, ornithine, and 
homoarginine, and 
(c) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, 
AA 4 is selected from the group consisting of: 
(a) a single bond, 
(b) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, proline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine,. 
histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
ornithine, and homoarginine, and 
(c) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, except that if AA3 is a single bond, AA 4 
is not tryptophan or phenylalanine, 
X is selected from the group consisting of H, NH2-
CO-, NH2-CS-, NH2-S02-, Y-NH-CO-, 
5,686,419 
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Y-NH-CS-, Y-NH-S0 2-, Y-CS-, 
Y-S02-, Y-0-CO-, Y-0-CS-, and 
U-CO-, 
y is selected from the group consisting of cl-(; alkyl, cl-(; 
fluoroalkyl, cl-(; alkyl substituted with K, cl-(; fluo- 5 
roalkyl substituted with K, 9-fluorenylmethyl, phenyl, 
phenyl substituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, naphthyl, naphthyl substi-
tuted with J, naphthyl disubstituted with J, naphthyl 
trisubstituted with J, cl-(; alkyl with an attached phenyl 10 
group, cl-(; alkyl with two attached phenyl groups, 
cl-(; alkyl with an attached phenyl group substituted 
with J, and cl-(; alkyl with two attached phenyl groups 
substituted with J, and 
U is selected from the group consisting of C1_6 15 
fluoroalkyl, cl-(; alkyl substituted with K, cl-(; fluo-
roalkyl substituted with K, 9-fluorenylmethyl, phenyl, 
phenyl substituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, naphthyl, naphthyl substi-
tuted with J, naphthyl disubstituted with J, naphthyl 20 
trisubstituted with J, cl-(; 6 alkyl with an attached 
phenyl group, Cl-6 alkyl with two attached phenyl 
groups, cl-(; 6 alkyl with an attached phenyl group 
substituted with J, and C1-(j alkyl with two attached 
phenyl groups substituted with J, and 25 
K is selected from the group consisting of halogen, 
COOH, OH, CN, N02 , NH2, C1-(j alkoxy, C1-(j 
alkylamine, cl-(; dialkylamine, cl-(; alkyl-0--CO-, 
C1-(j alkyl-0--CO-NH, and C1-(j alkyl-S-. 
2. A compound according to claim 1 wherein R is selected 30 
from the group consisting of 
(a) 3-amidinophenyl, 
(b) 4-amidinophenyl, 
(c) 3-amidinobenzyl, 
( d) 4-amidinobenzyl, 
(e) 3-guanidinophenyl, 
(f) 4-guanidinophenyl, 
(g) 3-guanidinobenzyl, and 
(h) 4-guanidinobenzyl. 
3. A compound according to claim 2 wherein 
AA 2 is an amino acid residue selected from the group 
consisting of alanine, glycine, isoleucine, leucine, 
proline, phenylalanine, threonine, serine, and valine, 
AA3 is selected from the group consisting of 
(a) a single bond, 
(b) an amino acid residue selected form the group 
consisting of alanine, glycine, isoleucine, leucine, 
and valine, 
AA 4 is single bond, 
X is selected from the group consisting of H, Y-SOn 
Y-0--CO-, and U-CO-, 
35 
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4. A compound according to claim 1 wherein R is selected 
from the group consisting of 
(a) -CH2CH2CH2NH-C( NH)NH2, 
(b)-CH2CH2CH2CHiNff2 , and 
(c)-CH2CH2CHiNff2• 
5. A compound according to claim 4 wherein 
AA 2 is an amino add residue selected from the group 
consisting of alanine, glycine, isoleucine, leucine, 
proline, phenylalanine, threonine, serine, and valine, 
AA3 is selected from the group consisting of 
(a) a single bond, 
(b) an amino acid residue selected from the group 
consisting of alanine, glycine, isoleucine, leucine, 
and valine, 
AA 4 is a single bond, 
X is selected from the group consisting of H, Y-S02, 
Y-0--CO-, and U-CO-, 
Y is selected from the group consisting of C1-(j alkyl, 
9-fluorenylmethyl, phenyl, cl-(; alkyl with an attached 
phenyl group, and cl-(; alkyl with two attached phenyl 
groups, and 
U is selected from the group consisting of 
9-fluorenylmethyl, cl-(; alkyl with an attached phenyl 
group, and C1-(j alkyl with two attached phenyl groups. 
6. A compound selected from the group consisting of: 
(a) H-(4-AmPhGlyf(OPhh, 
(b) Cbz-( 4-AmPhGlyf (OPh)i, 
(c) H-(3-AmPhGlyf(OPh)2, 
(d) Cbz-(3 -AmPhGly)P(0Ph)2 , 
(e) Cbz-Pro-(4-AmPhGly)P(OPhb 
(f) D-Phe-Pro-(4-AmPhGlyf(OPhb 
(g) Boc-D-Phe-L-Pro-(4-AmPhGlyf(OPh)i, 
(h) 2-NpS02-Gly-(4-AmPhGlyf(OPh)i, 
(i) Boc-Phe-Phe-(4-AmPhGlyf (OPh)i, 
G) Benzoyl-NHCH(4-NH2-C6H4 )P0(0Ph)i, 
(k) H-(4-AmPhe)P(OPh)i, 
(1) Cbz-(4-AmPhe)P(OPh)i, 
(m) Cbz-Pro-(4-AmPhef(OEt)2, 
(n) Boc-D-Phe-Pro-(4-AmPhef(OPh)i, 
( o) D-Phe-Pro-( 4-AmPhef (OPhh, 
(p) Cbz-Thr-(4-AmPhGlyf(OPh)i, 
(q) Boc-Leu-Thr-(4-AmPhGlyf(OPh)i, 
(r) H-(4-AmPhGlyf(OPh-4-Clh, and 
(s) Cbz-(4-AmPhGlyf(OPh-4-Cl)i. 
y is selected from the group consisting of cl-(; alkyl, 
9-fluorenylmethyl, phenyl, cl-(; alkyl with an attached 
phenyl group, and cl-(; alkyl with two attached phenyl 
groups, and 
7. A process for inhibiting serine protease activity com-
prising the step of adding to a medium containing the 
protease that amount of the compound of claim 1 effective 
to inhibit said activity. 
55 8. A method of decreasing blood coagulation comprising 
U is selected from the group consisting of 
9-fiuorenylmethyl, phenyl, cl-(; alkyl with an attached 
phenyl group, and cl-(; alkyl with two attached phenyl 
groups. 
the administration to a mammalian species in need of such 
treatment a therapeutically effective amount of the com-
pound of claim 1. 
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